

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A study protocol for a national observational cohort investigating frailty, delirium and multimorbidity in older Surgical Patients: The Third Sprint National Anaesthesia Project (SNAP 3)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-076803
Article Type:	Protocol
Date Submitted by the Author:	16-Jun-2023
Complete List of Authors:	Swarbrick, Claire; University of Nottingham, Anaesthesia & Critical Care; Royal Devon and Exeter NHS Foundation Trust, Anaesthesia Poulton, Tom; University of Melbourne Victorian Comprehensive Cancer Centre, Anaesthesia, Perioperative Medicine, and Pain Medicine; University College London, Critical Care Martin, Peter; University College London, Applied Health Research Partridge, Judith; King's College London, Division of Health and Social Care Research; Guy's and St Thomas' NHS Foundation Trust, Department of Ageing and Health Moppett, Iain; University of Nottingham, Anaesthesia & Critical Care; Nottingham University Hospitals NHS Trust, Anaesthesia SNAP 3 Project Team, SNAP 3 Project Team; Royal College of Anaesthetists, Centre for Research & Improvement
Keywords:	Adult anaesthesia < ANAESTHETICS, Dementia, GERIATRIC MEDICINE, Health Services for the Aged, Adult surgery < SURGERY

SCHOLARONE™
Manuscripts

1
2
3 1
4 2
5 3
6 3
7 4 **A study protocol for a national observational cohort investigating frailty,**
8 **delirium and multimorbidity in older Surgical Patients: The Third Sprint**
9 **National Anaesthesia Project (SNAP 3)**
10 6
11 7
12 8

13 9 Authorship: C Swarbrick, T Poulton, P Martin, JSL Partridge, I Moppett on behalf of the SNAP
14 10 3 Project Team
15 11

16 12 Dr Claire Swarbrick, University of Nottingham, Medical School, Nottingham, NG7 2UH,
17 13 ORCID 0000-0002-9448-2316
18 14

19 15 Dr Thomas Poulton, Department of Targeted Intervention, University College London,
20 16 London, UK; Department of Critical Care, University of Melbourne, Melbourne, Australia;
21 17 Department of Anaesthesia, Perioperative Medicine, and Pain Medicine, Peter MacCallum
22 18 Cancer Centre, Melbourne, Australia
23 19

24 20 Dr Peter Martin, Institute of Epidemiology and Healthcare, University College Hospital,
25 21 London, England
26 22

27 23 Dr Judith Partridge, Perioperative medicine for Older People undergoing Surgery, Guy's and
28 24 St Thomas' NHS Foundation Trust, London, England
29 25

30 26 Corresponding author: Professor Iain Moppett, School of Medicine, University of
31 27 Nottingham, Nottingham, England, iain.moppett@nottingham.ac.uk, 0115 951 5151
32 28

33 29 Word count: 5683 excluding title page, abstract, references, acknowledgements, competing
34 30 interests, author's contributions, funding statement
35 31

36 32 Keywords: frailty, multimorbidity, delirium, anaesthesia, surgery
37 33
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Introduction**

3 Older surgical patients are more likely to be living with frailty and multimorbidity and
4 experience postoperative complications. The routine management of these conditions in
5 the perioperative pathway is evolving. In order to support objective decision making for
6 patients, services and national guidance, accurate, contemporary data are needed to
7 describe the impact and associations between frailty, multimorbidity and processes of care
8 with patient and service level outcomes.
9

10 **Methods and analysis**

11 The study is comprised of an observational cohort study of approximately 7,500 surgical
12 patients; an organisational survey of perioperative services and a clinician survey of the
13 unplanned, medical workload generated from older surgical patients. The cohort will
14 consist of patients who are 60 years and older, undergoing a surgical procedure during a five
15 day recruitment period in participating UK hospitals. Participants will be assessed for
16 baseline frailty and multimorbidity; postoperative morbidity including delirium; and quality
17 of life. Data linkage will provide additional details about the patient, their admission and
18 mortality.
19

20 The study's primary outcome is length of stay, other outcome measures aim to capture
21 patient or process related metrics including incidence of postoperative morbidity and
22 delirium; readmission, mortality and quality of life. The cohort's incidence of frailty,
23 multimorbidity and delirium will be estimated using 95% confidence intervals. Their
24 relationships with outcome measures will be examined using unadjusted and adjusted
25 multilevel regression analyses. Choice of covariates in the adjusted models will be based on
26 directed acyclic graphs representing hypothesised causal pathways, which will be specified
27 prior to analysis. We will follow the recommendations of the STROBE statement when
28 reporting results.
29

30 A parallel study is planned in Australia to take place in 2022/2023.
31

32 **Ethics and dissemination**

33 The study has received the following approvals: Scotland A Research Ethics Committee and
34 Wales Research Ethics Committee 7. The cohort study requires the participant's consent or
35 a consultee's advice if a participant doesn't have capacity. It is essential to include those
36 who lack capacity, because conditions such as dementia are associated with increased
37 frailty, multimorbidity and delirium.
38

39 This work hopes to influence the development of services and guidelines. We will publish
40 our findings in peer reviewed journals and provide summary documents to our participants,
41 recruiting sites, healthcare policy makers and the public.
42

43 **Registration details**

44 International Standard Randomised Controlled Trial Number 40636, registered 23rd
45 December 2021.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Strengths and limitations of this study

- The breadth of UK hospital engagement and inclusivity of the study will allow conclusions applicable to countries with similarly developed healthcare systems.
- Inclusion of those without capacity has been encouraged with the use of consultees, this aims to reduce sampling bias of inappropriate exclusion.
- Recruitment will occur over a short period which may result in our dataset not being truly representative of the emergency surgical work carried out across the week.
- We have taken a balanced approach between pragmatism and meticulous identification of outcomes by combining clinical assessment with a retrospective notes review.
- There is a reasonable chance of losing participants to follow up. We have minimised the chances of this occurring by providing email reminders to local investigators; offering email or telephone outpatient follow up to participants and using data linkage to reduce participant burden.

INTRODUCTION

Background

The proportion of people aged 60 years or more undergoing surgery in England increased from 12.6% in 2000, to 17.8% in 2015 [1]. This is due to increased longevity; patient expectations of quality and length of life increasing; and advances in perioperative medicine, anaesthetic and surgical techniques [2].

Many older people benefit from surgery through an increase in longevity or an improvement in symptoms. Yet among surgical patients, older age, frailty and multimorbidity are associated with higher rates of postoperative morbidity, mortality, and adverse patient reported outcomes such as quality of life and loss of independence [3-14]. Frailty is characterised by physiological decline across multiple organ systems with multidomain loss of reserve, resulting in vulnerability to a range of adverse outcomes following a stressor event [15]. Multimorbidity is the presence of two or more co-existing chronic diseases in one individual [16]. The relationship between frailty and multimorbidity and their contribution to postoperative outcome in a surgical setting has not been thoroughly explored to date [17].

Delirium is a state of acute confusion that is commonly reversible and is characterised by fluctuating levels of attention and awareness; disorientation; memory impairment; disturbances of perception; and disorganised thinking [18]. It is one of the most frequently occurring postoperative complications in older adults. It is commonly reversible, and is preventable in approximately 40% of cases [19, 20]. Occurrence of delirium is associated with increased mortality at 12 months, as well as functional and cognitive decline [21, 22].

Frailty and delirium are geriatric syndromes which commonly coexist in older patients, however the details of their relationship is not fully understood. Those who are frail are vulnerable to minor stressors, and so might be expected to more commonly suffer with delirium and other poor outcomes [23, 24]. In a study of older patients recently discharged from hospital, those who were frail were found to be 2.5 times more likely to experience delirium than the corresponding non-frail population [25]. Another study of older vascular patients found that frailty was a strong predictor for delirium with an odds ratio (OR) of 5.66 (95% CI 1.53-21.03) [26]. Intuitively the presence of multimorbidity might also be expected to increase a patient's likelihood of suffering delirium. A study of older patients undergoing elective surgery found a relative risk of 1.75 for delirium in those suffering multimorbidity compared to those without [27].

The influence of frailty on a range of patient outcomes including postoperative quality of life, mortality, morbidity, reoperation, length of stay, readmission and discharge to residential care is widely reported [3, 4, 6, 28-30]. A review of older surgical patients by Lin et al., demonstrated a significant relationship with 12-month mortality, finding an OR of 1.1-4.97 for those living with frailty, compared to patients who were not frail [3, 31, 32]. Two of the studied papers also reported an association with two-year mortality (OR 4.01 (95% CI 2.61-6.16) [32]), and five-year mortality (OR 3.6 (95% CI 2.3-5.5 [33])). The review also highlighted an association between frailty and length of stay [3, 34-37]. This association was further demonstrated in a systematic review of acute surgical patients by Leiner et al. In

1
2
3 1 this meta-analysis, those living with frailty experienced an increased length of stay with a
4 2 weighted mean difference of 4.75 days (confidence interval (CI) 1.79-7.71, p=0.002) [29]. A
5 3 further meta-analysis by Panayi et al. found that surgical patients living with frailty were
6 4 more likely to experience postoperative complications (relative risk (RR) of 1.48, 95% CI
7 5 1.35-1.61, p<0.001), readmission (relative risk 1.61, 95% CI 1.44-1.80, p<0.001) and
8 6 discharge to skilled care (risk ratio 2.15, 95% CI 1.92-2.40, p<0.001) [30].
9
10
11

12 8 Routine assessment and management of frailty, multimorbidity and risk of postoperative
13 9 delirium can reduce the likelihood of adverse outcomes in older patients [2, 28, 38]. In
14 10 recent years, the specialty of perioperative medicine has brought together physicians,
15 11 geriatricians, anaesthetists, surgeons, nurses and allied healthcare professionals, to enhance
16 12 preoperative assessment; management and postoperative care of these patients. However,
17 13 the provision of this skilled and specialised service differs across the UK with the varying
18 14 degrees of resource allocation, local enthusiasm and operational priorities. Furthermore,
19 15 surgical pathways are heterogenous; often combining proactive and reactive services led by
20 16 different specialities. The criteria for accessing perioperative medicine services are diverse,
21 17 based on age, clinical need, surgical specialty, surgical procedure and clinician preference
22 18 [38-41].
23
24
25

26 20 There is no single metric that defines a 'good' outcome following surgery. Length of hospital
27 21 stay as a metric of outcome has been criticised due to the influence of social and
28 22 organisational factors. However, these factors are associated with frailty and
29 23 multimorbidity, and furthermore are important metrics at an organisational and financial
30 24 level in particular due to an ageing surgical population and resource constraints within
31 25 healthcare.
32
33
34

35 27 In order to support objective decision making for individual patients, services and national
36 28 planning, accurate, granular and contemporary data are needed describing the impact and
37 29 association between frailty, multimorbidity and processes of care with patient and service
38 30 level outcomes.
39
40

41 32 This study is called the Sprint National Anaesthesia Project 3 (SNAP 3). We have designed it
42 33 to describe the incidence of and relationships between frailty, multimorbidity and
43 34 postoperative delirium in the older surgical patient. This protocol will be used across
44 35 participating UK hospitals. Further research using an adapted SNAP 3 protocol is planned in
45 36 Australia. From our results we hope to provide suggestions for the future development of
46 37 perioperative care for the older surgical population.
47
48
49

50 39 **Objectives**

51 40 To describe the impact of frailty, multimorbidity and delirium, and their management, on
52 41 outcomes following surgery in patients aged 60 years and older undergoing surgery.
53
54

55 43 **Primary Objective:**

- 56 44 • O1: To describe the prevalence of frailty and multi-morbidity, and the incidence of
57 45 postoperative delirium in a surgical population aged 60 years or more.
58
59

60 47 **Secondary Objectives:**

- 1 • O2: To describe the bivariate associations between our three main variables of
2 interest – frailty, multimorbidity, delirium – with a range of patient and process
3 related outcomes.
- 4 • O3: To describe the univariate associations between frailty and delirium, as well as
5 multimorbidity and delirium, where delirium is viewed as an outcome.
- 6 • O4: To provide an estimate of the effects of frailty, multimorbidity and delirium on
7 primary and secondary outcomes with adjustment for clinically important
8 confounding factors including surgical speciality; surgical acuity; surgical complexity.
- 9 • O5: To establish the degree of agreement between three measures of patient frailty:
10 Clinical Frailty Scale, reported Edmonton Frailty Score, and Electronic Frailty Index.
- 11 • O6. To estimate proportions of patients who receive more in-depth perioperative
12 interventions, separately for those identified as frail when compared with patients
13 not identified as frail.
- 14 • O7: To develop and internally validate a risk prediction model for post-operative
15 delirium.
- 16 • O8: To describe the national provision of perioperative medicine services for older
17 people.
- 18 • O9: To identify associations between perioperative medicine for older people
19 services and primary and patient reported secondary outcomes.
- 20 • O10: To estimate the acute, unplanned workload for general and geriatric medicine
21 registrars generated by acute referrals for older surgical patients.
- 22 • O11: To identify associations between hospital level perioperative medicine services
23 and the workload from surgical patients referred to general and geriatrician medical
24 registrars.

25 METHODS

26 Study design and setting

27 The SNAP 3 programme of work consists of three components to be conducted in
28 participating hospitals across the UK:

- 29 S1. A five day, prospective, observational cohort study of those who are 60 years and
30 older, undergoing surgery to describe incidence, relationships and outcomes related
31 to frailty, multimorbidity and postoperative delirium.
- 32 S2. Organisational survey regarding the provision of perioperative medicine facilities for
33 older surgical patients.
- 34 S3. An observational, cross sectional survey of acute referrals from surgical specialities
35 to medicine and the provision of perioperative medicine training.

36
37
38 This protocol will be used in all participating UK sites and has been received favourable
39 opinion from the relevant ethics committees. The study will be replicated in Australia. Due
40 to differing regulations surrounding research, the protocol will be adapted for local
41 implementation outside of the UK and this adaptation will be published separately. Our
42 approach is modelled on the Donabedian framework of structure, process and outcomes
43 [42]. The methodology of the cohort study will be discussed in full below.

44 Organisational Survey S2:

45 Each site participating in SNAP 3 will be asked to complete an organisational survey.
46

1
2
3 1 This will describe the provision of perioperative medicine services at hospital level. We
4 2 hope this information will illustrate the range of perioperative medicine services and the
5 3 differing criteria used to access such services in different centres. One survey is requested
6 4 per hospital site via the Principal Investigator who could delegate the responsibility to a
7 5 more appropriate individual if necessary.
8
9

10
11 7 **Medical Registrar Survey S3:**

12 8 For a minimum of 24 hours, each general and geriatric medicine registrar (including middle
13 9 grade trainee or Trust grade equivalents) providing acute medical cover, will be asked to
14 10 complete a survey on the workload resulting from older surgical patients. The survey will
15 11 describe brief details of the medical problem, the nature of the review/advice given and any
16 12 perioperative medicine training they have received. The objective of this survey is to
17 13 quantify the unplanned workload experienced by general medical registrars and describe
18 14 associations between existing perioperative medicine services and burden on acute medical
19 15 services.
20
21
22

23 17 **Outcome measures**

24 18 SNAP 3 aims to detect outcomes relevant to professionals, patients and their relatives. We
25 19 have used multi-level outcome metrics to capture a breadth of informative outcome
26 20 markers.
27
28

29 22 Our primary outcome measure is length of stay in hospital after surgery, a well-recognised
30 23 measure of importance to healthcare services and patients. We recognise that length of
31 24 stay is influenced both by medical complications and discharge planning issues, both are
32 25 relevant to frailty, multimorbidity and delirium. A strength of the study is the measurement
33 26 of outcomes of importance to patients; days alive at home (DAH), days alive out of hospital
34 27 (DAOH) and quality of life (through us of the EQ-5D-5L and EQ-VAS).
35
36
37

38 29 **Secondary Outcomes:**

39 30 Secondary outcomes are important as complementary patient or process-relevant metrics.
40 31 These have been categorised into patient and process related outcomes, with some
41 32 crossover between these categories.
42
43

44 34 *Patient Related Secondary Outcomes:*

- 45 35 • Delirium incidence during the first seven days postoperatively; measured using 4AT
46 36 or Confusion Assessment Method for the Intensive Care Unit (CAM-ICU), and
47 37 retrospective notes review mapped to the Diagnostic and Statistical Manual of
48 38 Mental Disorders (DSM) 5 criteria for diagnosis of delirium [18, 43-45]
- 49 39 • Morbidity on postoperative days three and seven: measured using the
50 40 Postoperative Morbidity Score (POMS) [46-48]
- 51 41 • Mortality in hospital and at one, two, five and ten years
- 52 42 • Quality of life at four months postoperatively (measured using the EQ-5D-5L, EQ-
53 43 VAS)
- 54 44 • Days alive out of hospital (DAOH) and days at home (DAH) [49].
55
56
57
58

59 46 *Process Related Secondary Outcomes:*
60

- Number of referrals to acute medical services for older surgical patients, and the rate of such referrals by size of hospital (determined by number of beds).
- Readmission within 30-days of index surgical procedure, estimated using routinely collected hospital data (e.g. HES in England).

Eligibility criteria

Hospital level:

All NHS hospitals in the UK which carry out adult surgery (inpatient, day surgery or both) will be eligible to take part. Hospitals will be recruited through the National Institute of Academic Anaesthesia's Quality Audit and Research Coordinator (QuARC) and national Research and Innovation networks. The QuARC network consists of one or more research- / audit-interested anaesthetists in every NHS hospital who act as a contact, and in many cases also as the local lead investigator for Health Services Research Centre (HSRC) projects. There is also national network of research and innovation support in the UK NHS, which facilitates research support for eligible studies. As a consequence, in previous HSRC affiliated projects there has been near complete recruitment of eligible UK hospitals [50]. We aim to recruit >95% of eligible NHS hospitals for SNAP 3, but accept that this may be challenging due to the impact of SARS-CoV-2 on workforce and theatre operating.

Patient level:

Our inclusion criteria are deliberately broad, with the intention of including almost all patients who have surgery with a significant physiological stress response that could result in postoperative delirium or morbidity. Our exclusion criteria are limited and aim to minimise recruitment of participants whose clinical course is unlikely to provide information which answers our research questions.

Inclusion criteria:

Patients aged 60 years or older undergoing surgery during the recruitment period are eligible for this study. Surgery includes day-case, emergency, and elective procedures that require general, neuraxial, regional or local anaesthesia.

Exclusion criteria:

We will exclude patients undergoing invasive procedures that are diagnostic or likely to cause minimal physiological stress response, e.g. endoscopy, phacoemulsification, percutaneous tracheostomy insertion. Patients with American Society of Anesthesiologists Physical Status score grade VI are also excluded. See Appendix 1 for examples of included and excluded surgical procedures.

Data collection and follow up procedures for the cohort study

Recruitment for the SNAP 3 observational cohort study will occur over a five day period (Monday – Friday). The majority of sites are expected to recruit in the main recruitment window in March 2023. Allowance has been made for sites unable to recruit in the March window to recruit within 2 months. If we are unable to achieve our recruitment target, ethical approval has been given for a second recruitment period. Follow up involving direct participant contact will occur up to four months postoperatively. Data linkage with hospital records and ONS death registrations will be carried out at 120 days after discharge and at one, two, five and ten years postoperatively.

1
2
3
4 1
5 2 All sites will use an electronic Case Report Form (CRF) via a secure web-based portal
6 3 'REDCap'. An initial CRF record will be completed for each participant during the study
7 4 week. The CRF includes routinely collected demographics, medical history, surgical
8 5 information, blood laboratory data, SARS-CoV-2 status, surgical risk scores, socioeconomic
9 6 data and frailty assessments. Please see Appendix 2 for details of the data points collected.
10 7

11 8
12 9 There are two active frailty tools that require participant involvement and one passive frailty
13 10 score. The Clinical Frailty Scale (CFS) and the Reported Edmonton Frailty Score (rEFS) are
14 11 both brief and validated methods that do not require specifically trained personnel to
15 12 accurately assess frailty. The electronic Frailty Index (eFI) operationalises the deficit
16 13 accumulation model of frailty but is not available in all areas of the UK. It is calculated from
17 14 Primary Care data. The eFI will be recorded if it has been routinely collected. Those
18 15 carrying out frailty assessments were given details of relevant online training modules [51,
19 16 52]. The conventional cut off values for frailty will be used in analyses. Frailty will be
20 17 identified as CFS ≥ 5 , rEFS ≥ 8 and eFI ≥ 0.25 [28, 53, 54]. The choice of frailty tools aims to
21 18 first, accurately measure frailty in this sample and second, describe the routine usage of
22 19 different frailty tools across the four nations of the UK [53-59].
23 20

24 21
25 22
26 23 Process of care data will be recorded regarding the nature of preoperative assessment,
27 24 anaesthesia type, catheterisation and postoperative care level.
28 25
29 26

30 27
31 28 Multimorbidity is assessed through a list of relevant comorbidities which has been derived
32 29 from the Charlson Comorbidity Index and a priori knowledge of comorbidities relevant to
33 30 older patients with frailty and at risk of delirium [60]. The Elixhauser comorbidity index will
34 31 be calculated from HES data (or equivalent) following the method of Pritchard et al including
35 32 a one-year look back [61].
36 33
37 34

38 35
39 36 Participants who remain inpatients on days three and seven will be assessed for
40 37 postoperative morbidity using an appropriate speciality specific POMS and either the 4AT (if
41 38 not critically ill) or CAM-ICU (if critically ill) [45-48, 62]. Delirium and postoperative
42 39 morbidity will be assumed absent for those discharged alive on the day of surgery.
43 40
44 41

45 42
46 43 Those admitted for one or more nights will have a retrospective notes review to identify
47 44 delirium with the aim of minimising false negatives from researcher assessments alone. This
48 45 will include medical and nursing documentation, from the day of surgery, up to discharge or
49 46 day seven postoperatively, whichever is sooner. A tool has been developed to enable
50 47 objective researcher led retrospective notes evaluation. The tool was developed using DSM-
51 48 5 criteria for a diagnosis of delirium based on literature review and a priori knowledge of
52 49 language used by clinicians to describe delirium [63-68]. . Each diagnostic criterion from
53 50 DSM-5 has been mapped to a set of words and phrases which are commonly used to
54 51 describe that specific clinical feature.
55 52
56 53

57 54
58 55 We aim to minimise the number of missed delirium episodes by combining the findings of
59 56 the notes review and POMS with either the 4AT or CAM-ICU. This pragmatic approach to
60 57 the identification of delirium is proposed due to the inherent difficulty in measuring a
61 58 fluctuating condition with limited resource.
62 59
63 60

1
2
3
4 1
5 2 Quality of life will be assessed via email or telephone follow up at 120 days after surgery.
6 3 The mode of follow up is determined by the participant or their representative. If a
7 4 participant or their representative has opted into both email and telephone follow up but
8 5 does not respond to email, the local investigator will be emailed to prompt a telephone call.
9 6 The EQ-5D-5L and EQ-VAS are validated tools that do not require specific training for
10 7 accurate use [69]. We will also determine the 'days at home' (DAH) and 'days alive and out
11 8 of hospital' (DAOH) at 120 days as a measure of the process of recovery that has been
12 9 shown to be of importance to patients [70]. Days alive and out of hospital is available from
13 10 central records, and hence easier to collect at scale, but excludes time in residential or
14 11 nursing home care, outcomes which are often feared by older patients. Days at home, is
15 12 more difficult to capture, but more closely aligns with what patients want from a good
16 13 recovery. A possible by product of the study is a demonstration of whether the collection of
17 14 DAH is worth the additional research burden.
18
19
20
21
22

23 16 Data linkage via national government held and hospital level datasets will enable us to
24 17 provide more detailed outcome data without further patient or Local Investigator burden.
25 18 We will collaborate with NHS Digital, Digital Health and Care Wales, Electronic Data
26 19 Research and Innovation Service, National Services Scotland and individual Northern Irish
27 20 hospitals to provide as much of the long-term outcome data as possible. Due to individual
28 21 countries differing legislation and record keeping, data obtained will vary across the
29 22 devolved nations.
30
31

32 24 **Data collection for the clinician surveys**

33 25 The organisational survey, S2 will be distributed via email with a direct link to the REDCap
34 26 data entry portal. S3 will be administered by researchers (anaesthetists, physicians or
35 27 research nurses), who will contact medical registrars at the end of an on-call shift. This may
36 28 be done over the telephone or face to face. The researcher will input their answers directly
37 29 into REDCap. There will be no ongoing follow up of clinicians.
38
39

40 31 **Analysis plan**

41 32 Study Cohort:

42 33 Descriptive statistics will be used to describe the basic demographics of our participants and
43 34 key features of our participating sites.
44
45

46 36 Missing Data:

47 37 As with any large study with multiple follow up surveys, there will be missing data. The
48 38 number and proportion of missing observations will be documented in each analysis. For
49 39 each variable, we will assess the likely process that led to missing data, to determine
50 40 whether the data are missing at random or not missing at random. This will determine the
51 41 choice of an appropriate method of dealing with missing data, for example multiple
52 42 imputation.
53
54

55 43
56 44 Analysis per objective:

57 45 *Objective 1: Estimating the incidences of frailty, multimorbidity and postoperative delirium*

58 46 We will estimate the incidences of our three target variables as the proportion of patients
59 47 living with frailty and /or multimorbidity, and who experience delirium, respectively. We will
60

1
2
3 1 calculate 95 % confidence intervals using the binomial distribution. We will conduct
4 2 sensitivity analyses with inverse probability weights for elective and emergency procedures
5 3 in order to account for the absence of weekend data. We have already obtained estimates
6 4 of the number of emergency and selective procedures carried out at weekends from
7 5 selected hospitals, and will use those to estimate the inverse probability weights.
8
9 6

10 7 *Objective 2 & 3: Bivariate analyses*

11 8 The relationships between frailty, multimorbidity, delirium, primary and secondary
12 9 outcomes will be reported with appropriate models chosen for different outcome types:
13 10 multilevel logistic quantile or linear regression. We will account for clustering of patients in
14 11 hospitals through a random effect for hospitals within mixed-effects models.
15
16 12

17 13 *Objective 4: Multilevel regression models*

18 14 To investigate the relationships between frailty, multimorbidity, delirium and a range of
19 15 outcomes, we will use multilevel regression models adjusting for other clinically relevant
20 16 preoperative patient characteristics and type of surgery, with hospital-level random
21 17 intercepts to control for potential between-hospital differences in outcomes. Appropriate
22 18 models will be chosen for different outcome types: multilevel logistic regression for binary
23 19 outcomes, multilevel quantile regression for length of stay, DAOH and DAH, and multilevel
24 20 linear regression for the EQ-5D utility index. Prior to conducting these analyses, we will draw
25 21 directed acyclic graphs to clarify hypothesized causal relationships and to inform choices of
26 22 potential covariates that should be included, or indeed excluded, from our models.
27
28 23

29 24 *Objective 5: Agreement between frailty tools*

30 25 The analyses for objectives 1-3 will be reported separately for the different frailty measures
31 26 to gauge differences in their performance as predictors of outcome, using a range of
32 27 measures of performance as appropriate for the measurement levels of the various outcomes
33 28 [71]. We won't do the same for the multivariable analyses specified to address objective 4.
34 29 We will measure the pairwise consistency between the three frailty measures using
35 30 Spearman's correlation coefficients. To gauge agreement of clinical judgement in practice, we
36 31 will also assess agreement between dichotomized versions of the three frailty measures,
37 32 using their respective conventional cut-offs. Agreement between dichotomized frailty
38 33 measures will be assessed via percentage agreement and kappa coefficient.
39
40 34

41 35 *Objective 6: Descriptive statistics of interventions*

42 36 To address the objectives relating to hospital-level and patient-level interventions and
43 37 perioperative care designed to address risks associated with patient frailty, we will study the
44 38 sample of patients identified as living with frailty preoperatively and compare them to those
45 39 identified as not frail. We will document between-hospital differences in interventions and
46 40 procedures, using descriptive statistics and graphical methods.
47
48 41

49 42 *Objective 7: Risk prediction model for delirium*

50 43 Development and internal validation of a risk prediction model for delirium will involve the
51 44 following steps: (1) Exploratory and graphical analysis of the shapes of the relationships
52 45 between (numeric) candidate predictors, identified from previous studies and clinical insight,
53 46 and the probability of delirium. (2) Use of fractional polynomials or splines to identify suitable
54 47 transformations of numeric predictors, as appropriate. (3) Penalized logistic regression will
55
56
57
58
59
60

1
2
3 1 be considered for predictor selection, since these have been shown to outperform maximum
4 2 likelihood estimation and backward selection procedures in the development of risk models
5 3 [72]. (4) The discrimination of the risk model will be assessed using the C-statistic (area under
6 4 the ROC curve), which is to be estimated using optimism correction via bootstrapping [73].
7 5 We will also calculate the Brier score and investigate model calibration, using graphical
8 6 displays and the Hosmer-Lemeshow goodness-of-fit statistic. We will follow the TRIPOD
9 7 statement in reporting the development and internal validation of the risk prediction model
10 8 for delirium [74].
11 9

12
13
14 10 *Objective 8: Descriptive statistics of hospital level models of perioperative care*

15 11 The national provision of hospital level perioperative medicine services will be described. The
16 12 description will be sub-divided into care for elective and emergency patients; and degree of
17 13 preoperative and postoperative services.
18 14

19 15 *Objective 9: Associations between in-depth perioperative interventions and outcomes*

20 16 The role of in-depth perioperative interventions in modifying the risk of adverse outcomes in
21 17 patients with frailty will then be assessed using appropriate mixed effects models as for
22 18 objective 4. Patient-level covariates, such as age, socioeconomic status etc. will be included
23 19 as appropriate to distinguish the influence of population characteristics with hospital-level
24 20 perioperative interventions. Although there is inevitably a risk of significant unmeasured
25 21 confounding it is difficult to estimate the direction or magnitude of these effects.
26 22

27 23 *Objective 10: Acute referrals to medicine from older surgical patients*

28 24 Descriptive statistics will be used to describe the number and nature of acute referrals to
29 25 medicine from older surgical patients, and the rate of such referrals by size of hospital
30 26 (determined by number of beds). The nature of the referrals will be reported as resulting in
31 27 a telephone or face to face consultation. Referrals will be categorised by surgical speciality,
32 28 urgency of surgery and primary medical problem.
33 29

34 30 *Objective 11: Identify associations between perioperative medicine services and acute*
35 31 *referrals of older surgical patients to medicine*

36 32 To describe the associations between perioperative medicine services and acute referrals of
37 33 older surgical patients to medicine, we will use mixed effects logistic regression. Patient level
38 34 covariates will be included as appropriate to distinguish the relevant perioperative services.
39 35 Emergency surgery patients will not benefit from an elective perioperative medicine service
40 36 and so will be analysed separately.
41 37

42 38 **Subgroup analyses:**

43 39 Data will be reported according to pre-specified subgroups for objectives 1-6. Exact details
44 40 of subgroups will be finalised once the numbers of patients in potential groups is known. At a
45 41 minimum the following groups will be reported:

- 46 42 • Emergency and elective procedures
- 47 43 • Surgical invasiveness (using the method described by Abbot et al. [75])
- 48 44 • Major surgical specialty (e.g. orthopaedics, gynaecology)
- 49 45 • The 10 most common healthcare resource groups

50 46 Relevant subgroups will be analysed if they include at least 500 participants
51 47

1 Additional analyses and data sharing:

2 Investigators from outside the core study team may wish to conduct secondary analysis of
3 the data from SNAP 3. We recognise the importance of sharing data within the ethical and
4 legal constraints of the original participants' consent, in order to maximise the potential of
5 our dataset. Following a formal request for data sharing, the request will be considered by
6 the SNAP 3 Study Management Group (SMG) and Steering Committee. If the request is
7 made after the relevant groups have been disbanded, then the request will go directly to
8 the Chief Investigator who will consider the request alongside the Executive Management
9 Board of the HSRC.

10
11 There are many potential further analyses possible from the SNAP 3 dataset. We anticipate
12 developing and validating a multimorbidity score for our population. This will then be
13 compared with other measures of multimorbidity to evaluate its ability to predict primary
14 and secondary outcomes. Our secondary analysis plans will continue to evolve as we
15 understand the potential of our cohort's data.

16 **Sample size calculation**

17 Prior to the SARS-CoV-2 pandemic, the estimated achievable sample size for the
18 observational cohort study was around 12,000 participants based on English national data
19 (HES) and previous SNAP projects. We verified that this is a sufficient sample size to achieve
20 the primary and secondary objectives of this study. This estimate has been reduced to
21 8,000, in light of the impact of the pandemic on health services.

22
23
24 To estimate the proportion of patients living with frailty, and the proportion of patients who
25 develop delirium, a sample size of 7,203 is needed for a margin of error of 1 percentage
26 point (width of 95 % confidence interval: 2 percentage points). This calculation is based on
27 an outcome proportion of 0.25, which is a plausible conservative upper bound. The true
28 proportions are likely to be smaller, which would yield greater precision of the estimation of
29 the true proportion.

30
31 To estimate required sample sizes for the delirium risk prediction model, we followed
32 methods published by Riley et al [76]. We made the following assumptions:

- 33 • The number of candidate parameters in the risk prediction model is at most 30
- 34 • The proportion of patients with delirium is at least 0.05, and at most 0.25
- 35 • The Cox-Snell R-square of the prediction model is at least 0.05

36
37 These are conservative assumptions. Using the most conservative assumptions in each
38 calculation, the required sample sizes for the following desirable quality criteria are:

- 39 • Mean absolute error of predicted probabilities ≤ 0.01 : $n = 11,077$
- 40 • Shrinkage during model development using penalized regression methods $\leq 5\%$: $n = 5,395$
- 41 • Overoptimism of model performance $\leq 1\%$: $n = 8,909$

42 These are strict quality criteria, and they suggest that a sample size of around 11,000
43 patients is sufficient to estimate a high-quality clinical prediction model for delirium.

44
45
46 To achieve the objectives relating to hospital variation in, and effects of, processes and
47 procedures for treating patients with frailty, we plan to estimate multivariate mixed effects

1 models. There is no precise method for sample size calculations for these kinds of analyses.
2 A conservative lower bound of the percentage of patients with frailty in our achieved
3 sample is 10 %, which implies a minimum sample size of 1,200 patients with frailty. This will
4 give these analyses meaningful precision even in the presence of many covariates.

5
6 A priori subgroup analyses will be defined in the statistical analysis plan that will be
7 published separately before data-lock.

8 9 **ETHICS AND DISSEMINATION**

10 The study has received the following approvals: Scotland A Research Ethics Committee and
11 Wales Research Ethics Committee 7. Ethical approvals are obtained at national level. Local
12 confirmation of capacity and capability is provided by individual hospitals before study
13 commencement.

14 15 **Patient Consent**

16 All patients who are eligible for SNAP 3 inclusion will have capacity to consent assessed. Those
17 who have capacity to consent to study participation will provide electronic or written consent
18 after being provided with the Participant Information Sheet.

19
20 It is essential to include participants without capacity to consent to study participation in
21 order to minimise sampling bias due to exclusion of the target population. The objectives of
22 SNAP 3 relate directly to patients who have both acute and chronic cognitive impairment.
23 This study is of low participant burden and the new knowledge generated will improve care
24 for those without capacity. We will use the process of consultees (in England, Northern
25 Ireland and Wales) and Personal Legal Representatives (PLR, in Scotland) giving advice or
26 consent respectively.

27
28 Patient participants who lose capacity to consent:

29 We anticipate that a proportion of participants will lose capacity to consent during the
30 study, most commonly due to delirium. Whilst it is vital to continue including these
31 participants to fulfil our research objectives, their continued inclusion is complex, and
32 procedures vary depending on the country.

33 34 *England and Wales:*

35 Those who lose capacity to consent will be treated in accordance with section 34 of the
36 Mental Capacity Act (2005). Information gathered about the participant before loss of
37 capacity will continue to be used in the study. If further interventions are required, then
38 advice will be sought from a consultee for them to continue in the study.

39 40 *Northern Ireland and Scotland:*

41 Those who lose capacity to consent in Northern Ireland will be treated in accordance with
42 section 132 of the Mental Capacity Act (NI 2016). In the event that a previously consenting
43 participant loses capacity, their statement will still stand unless subsequently withdrawn. In
44 Scotland there is no specific legal provision for those who develop incapacity during
45 research studies. It is generally accepted practice to inform those consenting that they will
46 continue to be included in the study even if they develop incapacity.

1
2
3 1 Regardless of capacity, if a participant is distressed by ongoing inclusion in the study then
4 2 they will be withdrawn from the study.
5
6 3

7 4 **Study management**

8 5 The SMG is chaired by the Chief Investigator and meets at least monthly, to direct day to
9 6 day running of the project. The SMG members include those with clinical roles in
10 7 anaesthesia and geriatrics, a statistician, research management and PPI members. The
11 8 Study Steering Committee (SSC) meets at least annually to supervise the conduct of the
12 9 research and its progress achieving the study's objectives whilst working to the
13 10 protocol. We are fortunate to have multidisciplinary input from all interested clinical groups
14 11 and lay representation. We are responsible to the HSRC Executive Management Board. The
15 12 study sponsor is the University of Nottingham.
16
17 13

18 14 **Patients and public involvement**

19 15 The topic for SNAP 3 was selected through a competitive process of submissions open to all
20 16 anaesthetists across the UK. The panel for project selection included representatives from
21 17 patient and public involvement (PPI) groups, Royal College of Anaesthetists staff, clinicians
22 18 and trainees.
23
24 19

25 20 Our PPI members have provided valuable input into the design and conduct of the study via
26 21 the SMG and the SSC. They have been influential in the selection of outcome measures
27 22 especially relating to quality of life. Our PPI members have directly contributed to the
28 23 format and wording of the patient facing documentation and communication with sites.
29 24 They have also provided guidance on the acceptability of our study design in relation to
30 25 participant burden. PPI members will be involved in the publication of our results through
31 26 our dissemination plans and the production of future public facing documents.
32
33 27

34 28 **Dissemination**

35 29 We intend to present the results via our website (hosted by the HSRC), in peer reviewed
36 30 journals and through conference presentations. We will provide relevant summary reports
37 31 for the following groups:

- 38 32 1. Our participants- participants will be offered the opportunity to receive summary
39 33 findings up to three years after recruitment.
- 40 34 2. Our recruiting sites- all sites can receive an overall summary and can request a
41 35 hospital specific summary.
- 42 36 3. Healthcare policy makers- this will include medical and nursing royal colleges,
43 37 specialist societies, Department of Health, NHS England, NHS Wales, NHS Scotland
44 38 and Health and Social Care Ireland.
- 45 39 4. The public- relevant patient groups and charities will be informed of our results with
46 40 the assistance of our PPI members.
- 47 41 5. Participating NHS Trusts and Health Boards- all NHS Chief Executives will receive a
48 42 summary of the key findings.
49 43

50 44 All collaborators who recruit or collect data from participants, or complete clinician surveys
51 45 will be acknowledged in the manuscripts that arise from this study. Full details can be
52 46 obtained on our website.
53
54 47
55
56
57
58
59
60

ACKNOWLEDGEMENTS

We would like to acknowledge the hard work and enthusiasm of all of our Local Investigators, Trainee Principal Investigators, Principal Investigators, and the whole SNAP 3 Project Team; Christine Taylor, Karen Williams, Carol Green, Bob Evans, Akshay Shah, Laura Cortes and Jose Lourtie. We are grateful to the Research and Audit Federation of Anaesthetic Trainees and their local networks for their support of the study.

AUTHORSHIP STATEMENT

The following are members of the SNAP 3 Project Team: Iain Moppett (Co-chief Investigator, UK), Judith Partridge (Co-chief Investigator, UK), Thomas Poulton (Chief Investigator, Australia), Peter Martin (Study Statistician) and Claire Swarbrick (Trainee Lead, UK).

CONTRIBUTOR STATEMENT

IM initiated the collaborative project; is guarantor; the grant holder; revised the draft paper; cowrote the analysis plan and is analysing the data. CS obtained ethical approval; implemented the study in the UK; designed the data collection tools; monitored data collection for the study; cowrote the statistical analysis plan; cleaned and is analysing the data; and drafted and revised the paper. PM provided statistical expertise in study design and cowrote the analysis plan. JP provided expertise in geriatric medicine; designed data collection tools and revised the draft paper. TP implemented the study in Australia; designed data collection tools and revised the draft paper.

Karen Williams, Christine Taylor, Laura Courtes and Jose Lourtie provided organisational support throughout the study's conception, design phase and implementation. Karen Williams managed the day to day administrative needs of the project. Bob Evans and Carol Green are lay representatives who have provided their expertise into the design and implementation of the study. Akshay Shah provided expertise in perioperative medicine and designed data collection tools. The SNAP 3 Local Investigators provided the data (a full list of contributors will be published with the results paper).

All members of the SNAP 3 Project Team designed the study.

COMPETING INTERESTS

The authors declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

FUNDING STATEMENT

The study is generously funded by Royal College of Anaesthetists and the independent charity, the Frances and Augustus Newman Foundation. We are fortunate to receive support from the National Institute for Health Research Clinical Research Network. Neither of the funders have influenced the design or conduct of the study.

DATA STATEMENT

The data from the SNAP 3 study will be published in a data repository.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
REFERENCES

1. Fowler AJ, Abbott TEF, Prowle J, et al. Age of patients undergoing surgery. *Br J Surg*. 2019;106(8):1012-8.
2. Whitaker M HJ, Brownsell A. *Access All Ages*. Royal College of Surgeons; 2012.
3. Lin HS, Watts JN, Peel NM, et al. Frailty and post-operative outcomes in older surgical patients: a systematic review. *BMC Geriatr*. 2016;16(1):157.
4. Simon HL, Reif de Paula T, Profeta da Luz MM, et al. Frailty in older patients undergoing emergency colorectal surgery: USA National Surgical Quality Improvement Program analysis. *Br J Surg*. 2020;107(10):1363-71.
5. Thillainadesan J, Mudge AM, Aitken SJ, et al. The Prognostic Performance of Frailty for Delirium and Functional Decline in Vascular Surgery Patients. *J Am Geriatr Soc*. 2021;69(3):688-95.
6. Van de Ree CLP, Landers MJF, Kruithof N, et al. Effect of frailty on quality of life in elderly patients after hip fracture: a longitudinal study. *BMJ Open*. 2019;9(7):e025941.
7. Aitken RM, Partridge JSL, Oliver CM, et al. Older patients undergoing emergency laparotomy: observations from the National Emergency Laparotomy Audit (NELA) years 1-4. *Age Ageing*. 2020;49(4):656-63.
8. Eamer G, Taheri A, Chen SS, et al. Comprehensive geriatric assessment for older people admitted to a surgical service. *Cochrane Database of Systematic Reviews*. 2018(1).
9. Oliver CM, Bassett MG, Poulton TE, et al. Organisational factors and mortality after an emergency laparotomy: multilevel analysis of 39 903 National Emergency Laparotomy Audit patients. *Br J Anaesth*. 2018;121(6):1346-56.
10. Shipway D, Koizia L, Winterkorn N, et al. Embedded geriatric surgical liaison is associated with reduced inpatient length of stay in older patients admitted for gastrointestinal surgery. *Future Healthc J*. 2018;5(2):108-16.
11. Thu K, Nguyen HPT, Gogulan T, et al. Care of Older People in Surgery for general surgery: a single centre experience. *ANZ J Surg*. 2021;91(5):890-5.
12. Morris EJ, Taylor EF, Thomas JD, et al. Thirty-day postoperative mortality after colorectal cancer surgery in England. *Gut*. 2011;60(6):806-13.
13. Schweigert M, Solymosi N, Dubecz A, et al. Surgery for parapneumonic pleural empyema--What influence does the rising prevalence of multimorbidity and advanced age has on the current outcome? *Surgeon*. 2016;14(2):69-75.
14. Partridge JSL, Harari D, Martin F, et al. Randomized clinical trial of comprehensive geriatric assessment and optimization in vascular surgery. *Br J Surg*. 2017;104(6):679-87.
15. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *Lancet*. 2013;381(9868):752-62.
16. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet*. 2012;380(9836):37-43.
17. Hewitt J, McCormack C, Tay HS, et al. Prevalence of multimorbidity and its association with outcomes in older emergency general surgical patients: an observational study. *BMJ Open*. 2016;6(3):e010126.
18. American Psychiatric A. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5®)*. Washington, UNITED STATES: American Psychiatric Publishing; 2013.

19. Inouye SK, Bogardus ST, Jr., Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. *N Engl J Med.* 1999;340(9):669-76.
20. Wang YY, Yue JR, Xie DM, et al. Effect of the Tailored, Family-Involved Hospital Elder Life Program on Postoperative Delirium and Function in Older Adults: A Randomized Clinical Trial. *JAMA Intern Med.* 2019.
21. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. *Lancet.* 2014;383(9920):911-22.
22. McCusker J, Cole MG, Dendukuri N, et al. Does delirium increase hospital stay? *J Am Geriatr Soc.* 2003;51(11):1539-46.
23. Teale E, Young J. Multicomponent delirium prevention: not as effective as NICE suggest? *Age and Ageing.* 2015;44(6):915-7.
24. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *The Lancet.* 2013;381(9868):752-62.
25. Verloo H, Goulet C, Morin D, et al. Association between frailty and delirium in older adult patients discharged from hospital. *Clin Interv Aging.* 2016;11:55-63.
26. Thillainadesan J, Aitken SJ, Monaro SR, et al. Geriatric Comanagement of Older Vascular Surgery Inpatients Reduces Hospital-Acquired Geriatric Syndromes. *J Am Med Dir Assoc.* 2022;23(4):589-95 e6.
27. Cizginer S, Marcantonio E, Vasunilashorn S, et al. The Cognitive Reserve Model in the Development of Delirium: The Successful Aging After Elective Surgery Study. *J Geriatr Psychiatry Neurol.* 2017;30(6):337-45.
28. Frailty Guideline Working Group Guideline for Perioperative Care for People Living with Frailty Undergoing Elective and Emergency Surgery. Centre for Perioperative Care and the British Geriatrics Society; 2021 22/09/21. <https://cpoc.org.uk/sites/cpoc/files/documents/2021-09/CPOC-BGS-Frailty-Guideline-2021.pdf>.
29. Leiner T, Nemeth D, Hegyi P, et al. Frailty and Emergency Surgery: Results of a Systematic Review and Meta-Analysis. *Front Med (Lausanne).* 2022;9:811524.
30. Panayi AC, Orkaby AR, Sakthivel D, et al. Impact of frailty on outcomes in surgical patients: A systematic review and meta-analysis. *Am J Surg.* 2019;218(2):393-400.
31. Sündermann S, Dademasch A, Rastan A, et al. One-year follow-up of patients undergoing elective cardiac surgery assessed with the Comprehensive Assessment of Frailty test and its simplified form. *Interactive CardioVascular and Thoracic Surgery.* 2011;13(2):119-23.
32. Patel KV, Brennan KL, Brennan ML, et al. Association of a modified frailty index with mortality after femoral neck fracture in patients aged 60 years and older. *Clin Orthop Relat Res.* 2014;472(3):1010-7.
33. Ommundsen N, Wyller TB, Nesbakken A, et al. Frailty Is an Independent Predictor of Survival in Older Patients With Colorectal Cancer. *The Oncologist.* 2014;19(12):1268-75.
34. Green P, Woglom AE, Genereux P, et al. The Impact of Frailty Status on Survival After Transcatheter Aortic Valve Replacement in Older Adults With Severe Aortic Stenosis: A Single-Center Experience. *JACC: Cardiovascular Interventions.* 2012;5(9):974-81.
35. Hewitt J, Moug SJ, Middleton M, et al. Prevalence of frailty and its association with mortality in general surgery. *Am J Surg.* 2015;209(2):254-9.
36. Ambler GK, Brooks DE, Al Zuhir N, et al. Effect of frailty on short- and mid-term outcomes in vascular surgical patients. *British Journal of Surgery.* 2015;102(6):638-45.

- 1 37. Kistler EA, Nicholas JA, Kates SL, et al. Frailty and Short-Term Outcomes in Patients
2 With Hip Fracture. *Geriatr Orthop Surg Rehabil.* 2015;6(3):209-14.
- 3 38. Lees NP, Peden CJ, Dhesei JK, et al. The High Risk General Surgical Patient: Raising the
4 Standard. London: Royal College of Surgeons; 2018.
- 5 39. Needham MJ, Webb CE, Bryden DC. Postoperative cognitive dysfunction and
6 dementia: what we need to know and do. *Br J Anaesth.* 2017;119(suppl_1):i115-i25.
- 7 40. Royal College of Anaesthetists. Guidelines for the Provision of Anaesthesia Services
8 for the Perioperative Care of Elective and Urgent Care Patients 2022.
9 <https://www.rcoa.ac.uk/gpas/chapter-2>
- 10 41. Braude P, Partridge JS, Shipway D, et al. Perioperative medicine for older patients:
11 how do we deliver quality care? *Future Hosp J.* 2016;3(1):33-6.
- 12 42. Donabedian A. Evaluating the Quality of Medical Care. *The Milbank Memorial Fund*
13 *Quarterly.* 1966;44(3):166-206.
- 14 43. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for
15 rapid delirium screening: a study in 234 hospitalised older people. *Age Ageing.*
16 2014;43(4):496-502.
- 17 44. MacLulich AM, Shenkin SD, Goodacre S, et al. The 4 'A's test for detecting delirium in
18 acute medical patients: a diagnostic accuracy study. *Health Technol Assess.* 2019;23(40):1-
19 194.
- 20 45. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients:
21 validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit*
22 *Care Med.* 2001;29(7):1370-9.
- 23 46. Grocott MP, Browne JP, Van der Meulen J, et al. The Postoperative Morbidity Survey
24 was validated and used to describe morbidity after major surgery. *J Clin Epidemiol.*
25 2007;60(9):919-28.
- 26 47. Marufu TC, Elphick HL, Ahmed FB, et al. Short-term morbidity factors associated with
27 length of hospital stay (LOS): Development and validation of a Hip Fracture specific
28 postoperative morbidity survey (HF-POMS). *Injury.* 2019;50(4):931-8.
- 29 48. Sanders J, Keogh BE, Van der Meulen J, et al. The development of a postoperative
30 morbidity score to assess total morbidity burden after cardiac surgery. *J Clin Epidemiol.*
31 2012;65(4):423-33.
- 32 49. Foundation ER. EQ-5D-5L User Guide. EuroQol Research Foundation, Marten
33 Meesweg 107, 3068 AV Rotterdam, The Netherlands; 2019.
- 34 50. Moonesinghe SR, Wong DJN, Farmer L, et al. SNAP-2 EPICCS: the second Sprint
35 National Anaesthesia Project-Epidemiology of Critical Care after Surgery: protocol for an
36 international observational cohort study. *BMJ Open.* 2017;7(9):e017690.
- 37 51. Mclsaac DI, AIMS Research Group. Clinical Frailty Scale (CFS) Training Module
38 Articulate: The Ottawa Hospital; 2019 [Available from:
39 <https://rise.articulate.com/share/deb4rT02lvONbg4AfcMNRUudcd6QMts3#/>].
- 40 52. Mclsaac DI, AIMS Research Group. Edmonton Frail Scale Training Course Articulate:
41 The Ottawa Hospital; 2019 [Available from:
42 <https://rise.articulate.com/share/EM4TimhmYi0V9MpZCGebkTvn9hkmpx-X#/>].
- 43 53. Aucoin SD, Hao M, Sohi R, et al. Accuracy and Feasibility of Clinically Applied Frailty
44 Instruments before Surgery: A Systematic Review and Meta-analysis. *Anesthesiology.*
45 2020;133(1):78-95.

- 1 54. Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty
2 index using routine primary care electronic health record data. *Age Ageing*. 2016;45(3):353-
3 60.
- 4 55. Haren A, Lal R, Walker D, et al. Frailty assessment in older urological patients prior to
5 surgery: a systematic review and narrative synthesis. *Ther Adv Urol*.
6 2020;12:1756287220916614.
- 7 56. Partridge JS, Harari D, Dhesei JK. Frailty in the older surgical patient: a review. *Age*
8 *Ageing*. 2012;41(2):142-7.
- 9 57. Rolfson DB, Majumdar SR, Tsuyuki RT, et al. Validity and reliability of the Edmonton
10 Frail Scale. *Age Ageing*. 2006;35(5):526-9.
- 11 58. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and
12 frailty in elderly people. *CMAJ*. 2005;173(5):489-95.
- 13 59. Hilmer SN, Perera V, Mitchell S, et al. The assessment of frailty in older people in
14 acute care. *Australasian Journal on Ageing*. 2009;28(4):182-8.
- 15 60. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic
16 comorbidity in longitudinal studies: development and validation. *J Chronic Dis*.
17 1987;40(5):373-83.
- 18 61. Pritchard E, Fawcett N, Quan TP, et al. Combining Charlson and Elixhauser scores
19 with varying lookback predicated mortality better than using individual scores. *J Clin*
20 *Epidemiol*. 2021;130:32-41.
- 21 62. Jeong E, Park J, Lee J. Diagnostic Test Accuracy of the 4AT for Delirium Detection: A
22 Systematic Review and Meta-Analysis. *Int J Environ Res Public Health*. 2020;17(20).
- 23 63. Geriatric Medicine Research Collaborative. Retrospective delirium ascertainment
24 from case notes: a retrospective cohort study. *BMJ Open*. 2021;11(5):e042440.
- 25 64. Saczynski JS, Kosar CM, Xu G, et al. A tale of two methods: chart and interview
26 methods for identifying delirium. *J Am Geriatr Soc*. 2014;62(3):518-24.
- 27 65. Puelle MR, Kosar CM, Xu G, et al. The Language of Delirium: Keywords for Identifying
28 Delirium from Medical Records. *J Gerontol Nurs*. 2015;41(8):34-42.
- 29 66. Morandi A, Solberg LM, Habermann R, et al. Documentation and management of
30 words associated with delirium among elderly patients in postacute care: a pilot
31 investigation. *J Am Med Dir Assoc*. 2009;10(5):330-4.
- 32 67. Kuhn E, Du X, McGrath K, et al. Validation of a consensus method for identifying
33 delirium from hospital records. *PLoS One*. 2014;9(11):e111823.
- 34 68. Inouye SK, Leo-Summers L, Zhang Y, et al. A Chart-Based Method for Identification of
35 Delirium: Validation Compared with Interviewer Ratings Using the Confusion Assessment
36 Method. *Journal of the American Geriatrics Society*. 2005;53(2):312-8.
- 37 69. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of
38 life. *Health Policy*. 1990;16(3):199-208.
- 39 70. Jerath A, Austin PC, Wijeyesundera DN. Days Alive and Out of Hospital: Validation of a
40 Patient-centered Outcome for Perioperative Medicine. *Anesthesiology*. 2019;131(1):84-93.
- 41 71. Grudzinski AL, Aucoin S, Talarico R, et al. Comparing the predictive accuracy of frailty
42 instruments applied to preoperative electronic health data for adults undergoing noncardiac
43 surgery. *British Journal of Anaesthesia*. 2022;129(4):506-14.
- 44 72. Van Smeden M, Moons KG, de Groot JA, et al. Sample size for binary logistic
45 prediction models: Beyond events per variable criteria. *Stat Methods Med Res*.
46 2019;28(8):2455-74.

- 1
2
3 1 73. Austin PC, Steyerberg EW. Events per variable (EPV) and the relative performance of
4 2 different strategies for estimating the out-of-sample validity of logistic regression models.
5 3 Stat Methods Med Res. 2017;26(2):796-808.
6 4
7 4 74. Collins GS, Reitsma JB, Altman DG, et al. Transparent Reporting of a multivariable
8 5 prediction model for Individual Prognosis Or Diagnosis (TRIPOD). Ann Intern Med.
9 6 2015;162(10):735-6.
10 7
11 7 75. Abbott TEF, Fowler AJ, Dobbs TD, et al. Frequency of surgical treatment and related
12 8 hospital procedures in the UK: a national ecological study using hospital episode statistics.
13 9 Br J Anaesth. 2017;119(2):249-57.
14 10
15 10 76. Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing
16 11 a clinical prediction model. BMJ. 2020;368:m441.
17 12
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 1: SNAP 3 Examples of Included and Excluded Procedures

This list contains examples of included and excluded procedures for SNAP 3. We hope that it will be useful when making decisions regarding whether a participant should be approached for the study. It is not designed to be comprehensive, most surgical procedures are included. We have tried to not include the very minor procedures but it is challenging to know where to draw the line. We hope this guidance is useful.

Ophthalmology

Include	Exclude
Corneal grafts	Any procedure under topical anaesthesia
Scleral buckle	LASER (cornea, medical retina)
Eyelid reconstruction	Adnexal (eyelid surgery inc. ptosis, blepharoplasty)
Keratoplasty	Removal of oil from vitreous body
Excision of scalp/skin lesions if require a split skin graft (SSG) or flap	Excision of scalp/skin lesions not requiring a SSG or flap
Vitreoretinal surgery	Superficial eye lid surgery
Strabismus surgery	Vitrectomy using pars plana approach
Enucleation/eviscerations/orbital decompression	Correction of entropion of lower eyelid
Radioactive plaque insertion & removal	Dacryocystorhinostomy
Tantalum markers	Cataract surgery
Glaucoma surgery	Removal of sutures
Anterior orbitotomy	Needling
Trabeculectomy	Preserflo microshunt & mitomycin-C
Retinal surgery anaesthesia	Cataract surgery (regardless of anaesthesia mode)

General Surgery

Include	Exclude
Inguinal hernia repair under local anaesthesia +/- sedation	Lymph node biopsy
VAC dressing change	Simple dressing change
Perianal excision of rectal polyp	Diagnostic and therapeutic endoscopy regardless of anaesthesia mode
EUA rectum	
Manual evacuation	
Axillary clearance	
Oesophageal dilation/stenting	

ENT

Include	Exclude
Excision of larger lesions e.g basal cell carcinoma (BCC)/squamous cell carcinoma (SCC) e.g. requiring more than primary closure, SSG/flap. NB. Mode of anaesthetic here does not influence decision	Excision of smaller BCC/SCC e.g. no SSG/flap required. NB. Mode of anaesthetic here does not influence decision
Microlaryngoscopy	Biopsy of tongue
Minimally invasive parathyroidectomy	Frenuloplasty
Manipulation or examination under anaesthetic nose	Removal salivary tube
Cervical lymph node biopsy if GA	Tracheostomy insertion/change
Panendoscopy	Grommets
	Anaesthesia for diagnostic procedures
	Tracheo-oesophageal puncture
	Thyroplasties
	Tracheostomy insertion/change

Thoracics

Include	Exclude
Diagnostic bronchoscopy if with other procedure	Endobronchial ultrasound (EBUS)
Tracheal stenting	Diagnostic bronchoscopy alone
Rigid bronchoscopy	Diagnostic and therapeutic bronchoscopy/pleuroscopy
Mediastinoscopy	Chest drain as sole procedure
Video assisted thoracoscopic surgery (VATS)	
Endoscopic procedures performed ancillary to surgical procedure o Bronchoscopy prior to lung resection	

Cardiac

Include	Exclude
Transcatheter aortic valve implantation (TAVI)	Ablations
Other minimally invasive valve replacement procedures carried out under general anaesthesia	PPM lead extractions
	Angiography, percutaneous coronary intervention (PCI)

	Insertion of permanent pacemaker (PPM) / implantable cardioverter defibrillator (ICD)
	Cardioversion
	Electrophysiology (diagnostic or therapeutic)
	Insertion of intra-aortic balloon pump (IABP)

Hands

Include	Exclude
	Carpal tunnel decompression under local anaesthetic
	Dupuytren's palmar fasciectomy
	Trigger finger release
	Excision of hand lesion if small

Trauma & Orthopaedics Emergency Department

Include	Exclude
Ulnar nerve transposition	Aspiration of knee under local anaesthetic
Removal of metal work	Cheilectomy
Excision of olecranon bursa	Trigger point injections
Vertebroplasty	Therapeutic epidural injection
Trapeziectomy	Intra-articular joint injections
Knee replacement	Dupuytren's fasciectomy
Osteotomy of any bone	MUA joint
Replacement of hip joint	MUA fracture in ED
Replacement of shoulder joint	General anaesthesia/sedation for scanning/ICU management only
Small joint fusion	Post-arrest management
Insertion K wire	Erector spinae catheters
MUA fracture in theatre	Joint injections
Surgery for trauma	Joint aspiration
MUA fractures/dislocations in theatre	
Joint washout	

Urology

Include	Exclude
Rigid cystoscopy	Flexible cystoscopy
Urethral dilatation	Circumcision under local anaesthetic
Transurethral resection of bladder tumour	Standard circumcision under general anaesthetic
Transurethral resection of prostate	Transperineal prostate biopsy

Hydrocele under general anaesthetic	Flexible ureteroscopy
Laser fragmentation of stone	Cystoscopy under local anaesthesia
Nephrostomy	Prostate brachytherapy
TURP/TURBT	
Rigid diagnostic/surveillance cystoscopy	
Stent change	

Vascular

Include	Exclude
Fistula ligation and banding	Varicose veins under local anaesthetic
Fistula creation	
Endovascular aneurysm repair (EVAR)	

Interventional Radiology

Include	Exclude
EVAR	CT guided biopsies
Angioplasty	IV access/line insertion
CT guided drain	Endoscopic retrograde cholangiopancreatography (ERCP)

Dental

Include	Exclude
Extractions	

Gynaecology

Include	Exclude
Therapeutic hysteroscopy	Diagnostic hysteroscopy +/- biopsy
Laparoscopic hysterectomy	Hysteroscopy and smear
Cervical polypectomy	

Neurosurgery

Include	Exclude
Sympathetic nerve stimulator insertion or removal	SNS battery or lead change
Spinal cord stimulator insertion	SNS reprogramming
	SCS trial if purely percutaneous

Appendix 2: SNAP 3 Case Report Form

Below are the questions used in REDCap for the SNAP 3 study. For brevity, previously published, validated tools have not been replicated in this document. References for tools used in the SNAP 3 study can be found in the reference list of our accompanying paper.

1.0	Participant details				
1.1	Which country is your hospital based in?	England	Northern Ireland	Scotland	Wales
1.2	Which hospital site are you completing this form for?				
1.3	Is the potential participant having surgery AND 60 years or above?	Yes		No	
1.4	What is the planned date of surgery?				
1.5	Does the potential participant have the capacity to consent?				
1.6	Is there a consultee/Personal Legal Representative (PLR) to offer advice? This may be face to face or over the telephone.	Yes		No	
1.7	Is the participant's Consultee (England, Wales and Northern Ireland) or Personal Legal Representative (Scotland) available in person or over the telephone?	Yes		No	
1.8	Participant first name				
1.9	Participant surname				
1.10	Participant date of birth				
1.11	Participant NHS/CHI/H&C number				
1.12	Would the participant/Consultee/PLR be able to complete a survey at 4 months by email or telephone?	Yes by email	Yes by telephone	No	
1.13	Email address				
1.14	Telephone number				

2.0 Frailty assessment					
2.1	At any point during the participant's clinical pathway, were they assessed for frailty?	Yes		No	
2.2	Which frailty tool was used to assess the participant?	Clinical Frailty Scale /Rockwood Frailty Scale	Edmonton Frailty Scale (scored out of 17)	Reported Edmonton Frail Scale (scored out of 18)	Groningen Frailty Indicator
		Gait Speed Test	PRISMA-7	Risk Analysis Index-C	Timed Up and Go (TUG) Test
		Electronic Frailty Index	Hospital Risk Frailty Index	Grip Strength	Comprehensive Geriatric Assessment
2.3	What was the result of the frailty tool?				
2.4	Clinical Frail Scale (as completed by the clinical or research team)	1-9			
2.5	Reported Edmonton Frail Scale (as completed by the clinical or research team)	0-18			
2.6	Electronic frailty index	0-36			
3.0 Demographics and ADLs					
3.1	Postcode				
3.2	Ethnic group	Census categories			
3.3	Highest level of education	Degree level eg. degree, NVQ Level 4-5, Higher National Certificate, Higher National Diploma, BTEC Higher Level, professional	2+ A levels/VCEs, 4+ AS Levels, Higher School Certificate, NVQ Level 3, Advanced GNVQ, City and Guilds Advanced Craft, BTEC National, Scottish Higher	Apprenticeship	5 or more O Levels (passes)/CSEs (grade 1), School Certificate, 1 A Level, 2-3 AS Levels/VCEs, NVQ Level 2, Intermediate GNVQ, City and Guilds Craft, BTEC, Scottish Higher,

		qualifications (eg. teaching or nursing) or other equivalent higher education qualifications	National Diploma, Scottish Higher National Certificate, SVQ level 4+) or equivalent		Scottish Advanced Higher or equivalent qualifications
		O levels/CSEs (any grade), Foundation Diploma, NVQ level 1, Foundation GNVQ, O grade, Scottish Standard Grade or equivalent qualifications	No formal qualifications	Don't know	
3.4	Biological sex	Female		Male	
3.5	Weight				
3.6	Height				
3.7	BMI				
3.8	Source of admission	Own home	Sheltered housing, retirement complex	Residential home	Nursing home
		Rehabilitation facility (inpatient community unit or care home with the purpose of short term rehabilitation)	Homeless	Another secondary care hospital	Other, please specify

1					
2					
3					
4	3.9	Help with activities of daily living (ADLs)	No, the participant receives no help with ADLs or the participant has help for lifestyle reasons only (would easily be able to do the tasks if needed).	Needs help with any of the following: transportation, shopping, managing finances, shopping, meal preparation, house cleaning, managing communication with others, managing medications	Needs help with any of the following: ambulating, feeding, dressing, personal hygiene, continence, toileting.
5					
6					
7					
8					
9					
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					
21					
22					
23					
24					
25					
26					
27					
28					
29					
30					
31	4.0	Preoperative assessment			
32	4.1	How was the participant assessed preoperatively?	Nurse (or AHP) led assessment on day of surgery only	Anaesthetist led assessment on day of surgery only	Nurse (or AHP) led clinic
33			Physician (non geriatrician) led clinic	Geriatrician led clinic	MDT clinic
34			None of the above		Other
35					
36	4.2	Urgency of surgery as per NCEPOD criteria	Emergency	Urgent	Expedited
37					Planned
38					
39	4.3	Indication for surgery	Confirmed cancer	Possible cancer e.g. surgery with the aim of diagnosing possible cancer	Non-cancer
40					
41					
42					
43					
44					
45					
46					
47					
48	4.4		ASA I	ASA II	ASA III
49					ASA IV
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

	Which ASA score would you give the participant?	ASA V			
4.5	Surgical Outcome Risk Tool (SORT) Version 2 (including procedure type and surgical speciality, as completed by the clinical or research team)				
5.0 Comorbidities					
5.1	Does the participant have any of the following comorbidities?	MI (history of MI based on patient history, notes, history of stent	Heart failure (dyspnoea that has responded to heart failure treatment)	AF (paroxysmal/permanent AF, not if successfully ablated)	Valvular heart disease
		Hypertension (even if treated, do not include those with one isolated episode)	Peripheral vascular disease (treated and untreated)	COPD (probable clinical diagnosis)	Other chronic lung disease
		OSA/obesity hypoventilation syndrome (symptomatic, not purely positive STOP-BANG)	Cerebrovascular disease with mild or no residual symptoms (includes TIA, intracerebral/subarachnoid haemorrhage and stroke diagnosed on CT with no symptoms)	Hemiplegia or paraplegia (from any cause)	Dementia
		Mild cognitive	Anxiety or depression	Parkinson's disease	Diabetes (not just

		impairment	(on treatment)	or parkinsonism	impaired glucose tolerance or if in remission)
		Moderate or severe renal disease (acute or chronic, stage 3A+, eGFR < 60)	Benign prostatic hypertrophy (can be self reported)	Liver disease (with or without portal hypertension)	Peptic ulcer disease (even if treated and not symptomatic)
		Malignancy	Lymphoma (of any type, acute or chronic)	Leukaemia (of any type, acute or chronic)	Connective tissue/rheumatological disease (systemic lupus erythematosus, polymyositis, mixed connective tissue disease, polymyalgia rheumatica, psoriatic arthropathy or rheumatoid arthritis)

		Osteoarthritis (include self reported)	AIDS	Hearing impairment (uses hearing aids or struggles to manage a conversation at usual volumes of speech)	Visual impairment (registered partially sighted)
5.2	Does the participant have complications from their diabetes?	Diabetes without chronic complication		Diabetes with chronic complication	
5.3	How severe is the participant's liver disease?	Mild liver disease (without portal hypertension)		Moderate or severe liver disease (with portal hypertension)	
5.4	Which type(s) of malignancy does the participant have/has had?	Any solid malignancy without metastases		Metastatic solid tumour	
5.5	When was participant's malignancy/malignancies first diagnosed?	≤ 5 years ago		> 5 years ago	
6.0	Investigations within 12 weeks				
6.1	Haemoglobin g/L				
6.2	White cell count 10 ⁹ /L				
6.3	Neutrophil 10 ⁹ /L				
6.4	Lymphocyte 10 ⁹ /L				
6.5	Sodium mmol/L				
6.6	Potassium mmol/L				
6.7	Creatinine micromol/L				
6.8	eGFR ml/min/1.73 ²				

6.9	What is the participant's SARS-Cov-2 status preoperatively?	Tested positive or not tested and treated as positive	Tested negative or not tested and treated as negative	Don't know	
7.0 Day of procedure					
7.1	Date of operation				
7.2	Type of anaesthesia	General anaesthesia with volatiles	General anaesthesia with total intravenous anaesthesia (TIVA)	Neuraxial	Regional
		Sedation	Local infiltration	Don't know	
7.3	Was the participant catheterised?	No	Long-term/pre-admission catheter	Electively catheterised pre/intra-op	Catheterised post-op
7.4	What level of care did the participant receive postoperatively (on the day of surgery)?	Ward (level 0 or 1 care, including day case units)	Unplanned admission to PACU or equivalent (level 1.5 care)	Unplanned admission to PACU or equivalent (level 2/3 care)	Unplanned critical care admission (level 2 or 3 care)
		Planned admission to PACU or equivalent (level 1.5 care)	Planned admission to PACU or equivalent (level 2/3 care)	Planned critical care admission (level 2 or 3 care)	Don't know
7.5	Was the participant a day case patient who has been successfully discharged?	Yes, they have been discharged on the day of surgery	No, they are planned to be an inpatient OR they were intended to be day case but haven't been	Don't know	

			discharged on the day of surgery		
8.0	Day 3 follow up				
8.1	Postoperative Morbidity Survey (general/cardiac/fractured neck of femur, as completed by the research team)				
8.2	Documented new confusion or delirium	Yes	No		
8.3	4AT (if the participant isn't critically unwell, as completed by the clinical or research team)	0-12			
8.4	CAM-ICU (if the participant is critically unwell, as completed by the clinical or research team)	Negative		Positive	
8.5	Does the participant recall any symptoms of postoperative delirium or 'acute confusion'?	Yes		No	
9.0	Day 7 follow up				
9.1	Postoperative Morbidity Survey (general/cardiac/fractured neck of femur, as completed by the research team)				
9.2	Documented new confusion or delirium	Yes	No		
9.3	4AT (if the participant isn't critically unwell, as completed by the clinical or research team)	0-12			
9.4	CAM-ICU (if the participant is critically unwell, as completed by the clinical or research team)	Negative		Positive	
9.5	Does the participant recall any symptoms of	Yes		No	

	postoperative delirium or 'acute confusion'?				
10.0	Delirium notes review				
	<p>SNAP 3 will use the validated 4AT and CAM-ICU to detect delirium in participants postoperatively. Due to its fluctuating nature, some participants will not be experiencing delirium at the time of their follow up even though they have had delirium. We would like to maximise the likelihood of detecting delirium by undertaking a notes review on day seven in addition to the validated assessment tools.</p> <p>The notes review will provide the study with an impression of whether or not a patient experienced delirium outside of the time of their delirium assessment. Based on existing literature, a notes review is more likely to detect delirium which occurs at night and hyperactive delirium, than a single assessment (such as CAM) alone. The diagnosis of delirium is often not clearly documented in patient's notes. Estimates of previously unrecognised delirium from retrospective notes are variable, ranging from 7-43%. Nursing notes are more likely than medical notes to document the presence of keywords indicating delirium.</p> <p>The use of DSM-V criteria expanded with words describing delirium have been selected based on previous literature and a priori knowledge. Please review the nursing and medical notes as below. Only record evidence from (up to and including) day seven postoperatively. If there is evidence of delirium occurring on day eight, then please do not report this. If you believe that you have identified a current diagnosis of unrecognised delirium from the notes then please pass these concerns to the clinical team. This is a requirement of good clinical and research practice.</p>				
10.1	If the participant has a diagnosis of delirium documented either using a validated tool or as free text documentation of 'delirium' or 'delirious', then please select 'Positive diagnosis of delirium'	Positive diagnosis of delirium	No explicit diagnosis of delirium	Don't know	
	The following questions summarise the DSM-V criteria for the diagnosis of delirium and give examples of words frequently used to describe delirium in the clinical notes.				
10.2	<p><u>DSM criteria A</u>: Is there any documentation of the following?</p> <p>Inattention, inattentive, distractable</p> <p>Muddled</p> <p>Drowsy, drowsiness</p>	Yes, phrases similar to the ones listed are used in the notes	No	Don't know	

	Unrousable, unresponsive Hypoactive Agitated, agitation Altered mental status Inability to count from 20-1 Inability to recite months of the year backwards				
10.3	DSM criteria B: Is there any documentation of the following? Acute confusion Fluctuating confusion Fluctuation in severity throughout the day Altered mental status, mental status change	Yes, phrases similar to the ones listed are used in the notes	No	Don't know	
10.4	DSM criteria C: Is there any documentation of the following? Confused, confusion Muddled Hallucination, hallucinating Reorientation, reorientated Disorientation, disorientated, Encephalopathy, encephalopathic, Agitated, agitation Inappropriate behaviour Restless, unsettled Aggressive Wandering Refusing observations/ interventions Uncooperative, not cooperating, Pulling lines out Combative Speaking nonsense Paranoid MoCA < 24 AMTS < 7	Yes, phrases similar to the ones listed are used in the notes	No	Don't know	

10.5	DSM criteria D1: Is the participant functioning at their cognitive baseline?	Yes (they are at their neurocognitive baseline according to available sources of evidence)	No	Don't know	
10.6	DSM criteria D2: If delirium is likely, could this disturbance be better explained by a severely reduced level of arousal or coma? <i>If suffering from delirium, are the participant's symptoms better explained by being severely obtunded, sedated or unconscious with a Richmond Agitation Sedation Scale of 4 or less?</i>	Yes	No	Delirium not likely	
	Positive diagnosis of delirium from notes review either from:	Documented diagnosis of delirium in notes	DSM criteria responses: Yes to 10.2, 10.3, 10.4 No to 10.5, 10.6		
11.0	4 month follow up				
11.1	EQ-5D-5L				
11.2	EQ-VAS	0-100			
11.3	From when you had your operation, until 120 days after surgery, how many days have you spent in any hospital? Please include any hospital admissions (including your initial admission for surgery) and rehabilitation in hospitals. If you have				

	been out of hospital since the day of surgery and the surgery was day case then write '0'	
11.4	From when you had your operation, until 120 days after surgery, how many days have you spent from home due to convalescing with family/friends/in residential homes. Don't include days spent socialising away from home or hospital admissions here. If you have been at home since the day of surgery and the surgery was day case then write '0'	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page/Line	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1/L4-6	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2/L10-18	Protocol paper so no results available
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4/L3- P5/L37	
Objectives	3	State specific objectives, including any prespecified hypotheses	P5/L39- P6/L24	
Methods				
Study design	4	Present key elements of study design early in the paper	P6/L26	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P6/L27- P7/L15- 37, P8/L39-47	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P8/L6- L37, P10/L2-22	
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P7/L17- P8/4, P9/L8- P10/L14, see also Appendix 2	Also see CRF appendix
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P9/L8- P10/L22	
Bias	9	Describe any efforts to address potential sources of bias	P3/L6, P3/L13- 16, P9/L34- 47, P10/L2-5	
Study size	10	Explain how the study size was arrived at	P13/L17- P14-L4	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P9/L15- 16, P9/L23-47	
Statistical methods	12	(a) Describe all statistical methods, including those used to	P10/L31-	

		control for confounding	P13/L15	
		(b) Describe any methods used to examine subgroups and interactions	P12/L38-46	
		(c) Explain how missing data were addressed	P10/L36-42	
		(d) If applicable, explain how loss to follow-up was addressed	Protocol paper so not possible	
		(e) Describe any sensitivity analyses	P11/L1-5	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Protocol paper so not possible.	
		(b) Give reasons for non-participation at each stage	Protocol paper so not possible.	
		(c) Consider use of a flow diagram	Protocol paper so not possible.	Protocol paper so not possible.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Protocol paper so not possible.	Protocol paper so not possible.
		(b) Indicate number of participants with missing data for each variable of interest	Protocol paper so not possible.	Protocol paper so not possible.
		(c) Summarise follow-up time (eg, average and total amount)	Protocol paper so not possible.	Protocol paper so not possible.
Outcome data	15*	Report numbers of outcome events or summary measures over time	Protocol paper so not possible.	Protocol paper so not possible.
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Protocol paper so not possible.	Protocol paper so not possible.
		(b) Report category boundaries when continuous variables were categorized	Protocol paper so not possible.	Protocol paper so not possible.
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Protocol paper so	Protocol paper so

			not possible.	not possible.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Protocol paper so not possible.	Protocol paper so not possible.
Discussion				
Key results	18	Summarise key results with reference to study objectives	Protocol paper so not possible.	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P3/L8-16	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Protocol paper so not possible.	Protocol paper so not possible.
Generalisability	21	Discuss the generalisability (external validity) of the study results	Protocol paper so not possible.	Protocol paper so not possible.
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P16/L40-44	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

A study protocol for a national observational cohort investigating frailty, delirium and multimorbidity in older Surgical Patients: The Third Sprint National Anaesthesia Project (SNAP 3)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-076803.R1
Article Type:	Protocol
Date Submitted by the Author:	07-Sep-2023
Complete List of Authors:	Swarbrick, Claire; University of Nottingham, Anaesthesia & Critical Care; Royal Devon and Exeter NHS Foundation Trust, Anaesthesia Poulton, Tom; University of Melbourne Victorian Comprehensive Cancer Centre, Anaesthesia, Perioperative Medicine, and Pain Medicine; University College London, Critical Care Martin, Peter; University College London, Applied Health Research Partridge, Judith; King's College London, Division of Health and Social Care Research; Guy's and St Thomas' NHS Foundation Trust, Department of Ageing and Health Moppett, Iain; University of Nottingham, Anaesthesia & Critical Care; Nottingham University Hospitals NHS Trust, Anaesthesia SNAP 3 Project Team, SNAP 3 Project Team; Royal College of Anaesthetists, Centre for Research & Improvement
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Epidemiology, Geriatric medicine
Keywords:	Adult anaesthesia < ANAESTHETICS, Dementia, GERIATRIC MEDICINE, Health Services for the Aged, Adult surgery < SURGERY

SCHOLARONE™
Manuscripts

1
2
3 1
4 2
5 3
6 3
7 4 **A study protocol for a national observational cohort investigating frailty,**
8 **delirium and multimorbidity in older Surgical Patients: The Third Sprint**
9 **National Anaesthesia Project (SNAP 3)**
10 6
11 7
12 8

13 9 Authorship: C Swarbrick, T Poulton, P Martin, JSL Partridge, I Moppett on behalf of the SNAP
14 10 3 Project Team
15 11

16 12 Dr Claire Swarbrick, University of Nottingham, Medical School, Nottingham, NG7 2UH,
17 13 Claire.swarbrick@nottingham.ac.uk, 0115 951 5151, ORCID 0000-0002-9448-2316
18 14

19 15 Dr Thomas Poulton, Department of Targeted Intervention, University College London,
20 16 London, UK; Department of Critical Care, University of Melbourne, Melbourne, Australia;
21 17 Department of Anaesthesia, Perioperative Medicine, and Pain Medicine, Peter MacCallum
22 18 Cancer Centre, Melbourne, Australia
23 19

24 20 Dr Peter Martin, Institute of Epidemiology and Healthcare, University College Hospital,
25 21 London, England
26 22

27 23 Dr Judith Partridge, Perioperative medicine for Older People undergoing Surgery, Guy's and
28 24 St Thomas' NHS Foundation Trust, London, England
29 25

30 26 Corresponding author: Professor Iain Moppett, School of Medicine, University of
31 27 Nottingham, Nottingham, England, iain.moppett@nottingham.ac.uk, ORCID 0000-0003-
32 28 3750-6067
33 29

34 30 Word count: 5681 excluding title page, abstract, references, acknowledgements, competing
35 31 interests, author's contributions, funding statement
36 32

37 33 Keywords: frailty, multimorbidity, delirium, anaesthesia, surgery
38 34
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Introduction**

3 Older surgical patients are more likely to be living with frailty and multimorbidity and
4 experience postoperative complications. The management of these conditions in the
5 perioperative pathway is evolving. In order to support objective decision making for
6 patients, services and national guidance, accurate, contemporary data are needed to
7 describe the impact and associations between frailty, multimorbidity and healthcare
8 processes with patient and service level outcomes.
9

10 **Methods and analysis**

11 The study is comprised of an observational cohort study of approximately 7,500 patients; an
12 organisational survey of perioperative services and a clinician survey of the unplanned,
13 medical workload generated from older surgical patients. The cohort will consist of patients
14 who are 60 years and older, undergoing a surgical procedure during a five day recruitment
15 period in participating UK hospitals. Participants will be assessed for baseline frailty and
16 multimorbidity; postoperative morbidity including delirium; and quality of life. Data linkage
17 will provide additional details about individuals, their admission and mortality.
18

19 The study's primary outcome is length of stay, other outcome measures include incidence of
20 postoperative morbidity and delirium; readmission, mortality and quality of life. The
21 cohort's incidence of frailty, multimorbidity and delirium will be estimated using 95%
22 confidence intervals. Their relationships with outcome measures will be examined using
23 unadjusted and adjusted multilevel regression analyses. Choice of covariates in the adjusted
24 models will be prespecified, based on directed acyclic graphs.
25

26 A parallel study is planned to take place in Australia in 2022.
27

28 **Ethics and dissemination**

29 The study has received approval from the Scotland A Research Ethics Committee and Wales
30 Research Ethics Committee 7.
31

32 This work hopes to influence the development of services and guidelines. We will publish
33 our findings in peer reviewed journals and provide summary documents to our participants,
34 sites, healthcare policy makers and the public.
35

36 **Registration details**

37 International Standard Randomised Controlled Trial Number 40636.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Strengths and limitations of this study

- The breadth of UK hospital engagement and inclusivity of the study will allow conclusions applicable to countries with similarly developed healthcare systems.
- Inclusion of those without capacity has been encouraged with the use of consultees, this aims to reduce sampling bias of inappropriate exclusion.
- Recruitment will occur over a short period which may result in our dataset not being truly representative of the emergency surgical work carried out across the week.
- We have taken a balanced approach between pragmatism and meticulous identification of outcomes by combining clinical assessment with a retrospective notes review.
- There is a reasonable chance of losing participants to follow up. We have minimised the chances of this occurring by providing email reminders to local investigators; offering email or telephone outpatient follow up to participants and using data linkage to reduce participant burden.

1 INTRODUCTION

2 Background

3 The proportion of people aged 60 years or more undergoing surgery in England increased
4 from 12.6% in 2000, to 17.8% in 2015 [1]. This is due to increased longevity; patient
5 expectations of quality and length of life increasing; and advances in perioperative
6 medicine, anaesthetic and surgical techniques [2].

7
8 Many older people benefit from surgery through an increase in longevity or an
9 improvement in symptoms. Yet among surgical patients, older age, frailty and
10 multimorbidity are associated with higher rates of postoperative morbidity, mortality, and
11 adverse patient reported outcomes such as quality of life and loss of independence [3-14].
12 Frailty is characterised by physiological decline across multiple organ systems with
13 multidomain loss of reserve, resulting in vulnerability to a range of adverse outcomes
14 following a stressor event [15]. Multimorbidity is the presence of two or more co-existing
15 chronic diseases in one individual [16]. The relationship between frailty and multimorbidity
16 and their contribution to postoperative outcome in a surgical setting has not been
17 thoroughly explored to date [17].

18
19 Delirium is a state of acute confusion that is commonly reversible and is characterised by
20 fluctuating levels of attention and awareness; disorientation; memory impairment;
21 disturbances of perception; and disorganised thinking [18]. It is one of the most frequently
22 occurring postoperative complications in older adults. It is commonly reversible, and is
23 preventable in approximately 40% of cases [19, 20]. Occurrence of delirium is associated
24 with increased mortality at 12 months, as well as functional and cognitive decline [21, 22].

25
26 Frailty and delirium are geriatric syndromes which commonly coexist in older patients,
27 however the details of their relationship is not fully understood. Those who are frail are
28 vulnerable to minor stressors, and so might be expected to more commonly suffer with
29 delirium and other poor outcomes [23, 24]. In a study of older patients recently discharged
30 from hospital, those who were frail were found to be 2.5 times more likely to experience
31 delirium than the corresponding non-frail population [25]. Another study of older vascular
32 patients found that frailty was a strong predictor for delirium with an odds ratio (OR) of 5.66
33 (95% CI 1.53-21.03) [26]. Intuitively the presence of multimorbidity might also be expected
34 to increase a patient's likelihood of suffering delirium. A study of older patients undergoing
35 elective surgery found a relative risk of 1.75 for delirium in those suffering multimorbidity
36 compared to those without [27].

37
38 The influence of frailty on a range of patient outcomes including postoperative quality of
39 life, mortality, morbidity, reoperation, length of stay, readmission and discharge to
40 residential care is widely reported [3, 4, 6, 28-30]. A review of older surgical patients by Lin
41 et al., demonstrated a significant relationship with 12-month mortality, finding an OR of 1.1-
42 4.97 for those living with frailty, compared to patients who were not frail [3, 31, 32]. Two of
43 the studied papers also reported an association with two-year mortality (OR 4.01 (95% CI
44 2.61-6.16) [32]), and five-year mortality (OR 3.6 (95% CI 2.3-5.5 [33]). The review also
45 highlighted an association between frailty and length of stay [3, 34-37]. This association was
46 further demonstrated in a systematic review of acute surgical patients by Leiner et al. In
47 this meta-analysis, those living with frailty experienced an increased length of stay with a

1
2
3 1 weighted mean difference of 4.75 days (confidence interval (CI) 1.79-7.71, $p=0.002$) [29]. A
4 2 further meta-analysis by Panayi et al. found that surgical patients living with frailty were
5 3 more likely to experience postoperative complications (relative risk (RR) of 1.48, 95% CI
6 4 1.35-1.61, $p<0.001$), readmission (relative risk 1.61, 95% CI 1.44-1.80, $p<0.001$) and
7 5 discharge to skilled care (risk ratio 2.15, 95% CI 1.92-2.40, $p<0.001$) [30].
8
9 6

10 7 Routine assessment and management of frailty, multimorbidity and risk of postoperative
11 8 delirium can reduce the likelihood of adverse outcomes in older patients [2, 28, 38]. In
12 9 recent years, the specialty of perioperative medicine has brought together physicians,
13 10 geriatricians, anaesthetists, surgeons, nurses and allied healthcare professionals, to enhance
14 11 preoperative assessment; management and postoperative care of these patients. However,
15 12 the provision of this skilled and specialised service differs across the UK with the varying
16 13 degrees of resource allocation, local enthusiasm and operational priorities. Furthermore,
17 14 surgical pathways are heterogenous; often combining proactive and reactive services led by
18 15 different specialities. The criteria for accessing perioperative medicine services are diverse,
19 16 based on age, clinical need, surgical specialty, surgical procedure and clinician preference
20 17 [38-41].
21
22 18

23 19 There is no single metric that defines a 'good' outcome following surgery. Length of hospital
24 20 stay as a metric of outcome has been criticised due to the influence of social and
25 21 organisational factors. However, these factors are associated with frailty and
26 22 multimorbidity, and furthermore are important metrics at an organisational and financial
27 23 level in particular due to an ageing surgical population and resource constraints within
28 24 healthcare.
29 25

30 26 In order to support objective decision making for individual patients, services and national
31 27 planning, accurate, granular and contemporary data are needed describing the impact and
32 28 association between frailty, multimorbidity and processes of care with patient and service
33 29 level outcomes.
34 30

35 31 This study is called the Sprint National Anaesthesia Project 3 (SNAP 3). We have designed it
36 32 to describe the incidence of and relationships between frailty, multimorbidity and
37 33 postoperative delirium in the older surgical patient. This protocol will be used across
38 34 participating UK hospitals. Further research using an adapted SNAP 3 protocol is planned in
39 35 Australia. From our results we hope to provide suggestions for the future development of
40 36 perioperative care for the older surgical population.
41 37

42 38 **Objectives**

43 39 To describe the impact of frailty, multimorbidity and delirium, and their management, on
44 40 outcomes following surgery in patients aged 60 years and older undergoing surgery.
45 41

46 42 **Primary Objective:**

- 47 43 • O1: To describe the prevalence of frailty and multi-morbidity, and the incidence of
48 44 postoperative delirium in a surgical population aged 60 years or more.
49 45

50 46 **Secondary Objectives:**

51 47
52
53
54
55
56
57
58
59
60

- 1 • O2: To describe the bivariate associations between our three main variables of
2 interest – frailty, multimorbidity, delirium – with a range of patient and process
3 related outcomes.
- 4 • O3: To describe the univariate associations between frailty and delirium, as well as
5 multimorbidity and delirium, where delirium is viewed as an outcome.
- 6 • O4: To provide an estimate of the effects of frailty, multimorbidity and delirium on
7 primary and secondary outcomes with adjustment for clinically important
8 confounding factors including surgical speciality; surgical acuity; surgical complexity.
- 9 • O5: To establish the degree of agreement between three measures of patient frailty:
10 Clinical Frailty Scale, reported Edmonton Frailty Score, and Electronic Frailty Index.
- 11 • O6. To estimate proportions of patients who receive more in-depth perioperative
12 interventions, separately for those identified as frail when compared with patients
13 not identified as frail.
- 14 • O7: To develop and internally validate a risk prediction model for post-operative
15 delirium.
- 16 • O8: To describe the national provision of perioperative medicine services for older
17 people.
- 18 • O9: To identify associations between perioperative medicine for older people
19 services and primary and patient reported secondary outcomes.
- 20 • O10: To estimate the acute, unplanned workload for general and geriatric medicine
21 registrars generated by acute referrals for older surgical patients.
- 22 • O11: To identify associations between hospital level perioperative medicine services
23 and the workload from surgical patients referred to general and geriatrician medical
24 registrars.

25 METHODS

26 Study design and setting

27 The SNAP 3 programme of work consists of three components to be conducted in
28 participating hospitals across the UK:

- 29 S1. A five day, prospective, observational cohort study of those who are 60 years and
30 older, undergoing surgery to describe incidence, relationships and outcomes related
31 to frailty, multimorbidity and postoperative delirium.
- 32 S2. Organisational survey regarding the provision of perioperative medicine facilities for
33 older surgical patients.
- 34 S3. An observational, cross sectional survey of acute referrals from surgical specialities
35 to medicine and the provision of perioperative medicine training.

36
37
38 This protocol will be used in all participating UK sites and has been received favourable
39 opinion from the relevant ethics committees. The study will be replicated in Australia. Due
40 to differing regulations surrounding research, the protocol will be adapted for local
41 implementation outside of the UK and this adaptation will be published separately. Our
42 approach is modelled on the Donabedian framework of structure, process and outcomes
43 [42]. The methodology of the cohort study will be discussed in full below.

44 Organisational Survey S2:

45 Each site participating in SNAP 3 will be asked to complete an organisational survey.
46

1
2
3 1 This will describe the provision of perioperative medicine services at hospital level. We
4 2 hope this information will illustrate the range of perioperative medicine services and the
5 3 differing criteria used to access such services in different centres. One survey is requested
6 4 per hospital site via the Principal Investigator who could delegate the responsibility to a
7 5 more appropriate individual if necessary.
8
9

10
11 7 **Medical Registrar Survey S3:**

12 8 For a minimum of 24 hours, each general and geriatric medicine registrar (including middle
13 9 grade trainee or Trust grade equivalents) providing acute medical cover, will be asked to
14 10 complete a survey on the workload resulting from older surgical patients. The survey will
15 11 describe brief details of the medical problem, the nature of the review/advice given and any
16 12 perioperative medicine training they have received. The objective of this survey is to
17 13 quantify the unplanned workload experienced by general medical registrars and describe
18 14 associations between existing perioperative medicine services and burden on acute medical
19 15 services.
20
21
22

23 17 **Outcome measures**

24 18 SNAP 3 aims to detect outcomes relevant to professionals, patients and their relatives. We
25 19 have used multi-level outcome metrics to capture a breadth of informative outcome
26 20 markers.
27
28

29 22 Our primary outcome measure is length of stay in hospital after surgery, a well-recognised
30 23 measure of importance to healthcare services and patients. We recognise that length of
31 24 stay is influenced both by medical complications and discharge planning issues, both are
32 25 relevant to frailty, multimorbidity and delirium. A strength of the study is the measurement
33 26 of outcomes of importance to patients; days alive at home (DAH), days alive out of hospital
34 27 (DAOH) and quality of life (through us of the EQ-5D-5L and EQ-VAS).
35
36
37

38 29 **Secondary Outcomes:**

39 30 Secondary outcomes are important as complementary patient or process-relevant metrics.
40 31 These have been categorised into patient and process related outcomes, with some
41 32 crossover between these categories.
42
43

44 34 *Patient Related Secondary Outcomes:*

- 45 35 • Delirium incidence during the first seven days postoperatively; measured using 4AT
46 36 or Confusion Assessment Method for the Intensive Care Unit (CAM-ICU), and
47 37 retrospective notes review mapped to the Diagnostic and Statistical Manual of
48 38 Mental Disorders (DSM) 5 criteria for diagnosis of delirium [18, 43-45]
- 49 39 • Morbidity on postoperative days three and seven: measured using the
50 40 Postoperative Morbidity Score (POMS) [46-48]
- 51 41 • Mortality in hospital and at one, two, five and ten years
- 52 42 • Quality of life at four months postoperatively (measured using the EQ-5D-5L, EQ-
53 43 VAS)
- 54 44 • Days alive out of hospital (DAOH) and days at home (DAH) [49].
55
56
57
58

59 46 *Process Related Secondary Outcomes:*
60

- Number of referrals to acute medical services for older surgical patients, and the rate of such referrals by size of hospital (determined by number of beds).
- Readmission within 30-days of index surgical procedure, estimated using routinely collected hospital data (e.g. HES in England).

Eligibility criteria

Hospital level:

All NHS hospitals in the UK which carry out adult surgery (inpatient, day surgery or both) will be eligible to take part. Hospitals will be recruited through the National Institute of Academic Anaesthesia's Quality Audit and Research Coordinator (QuARC) and national Research and Innovation networks. The QuARC network consists of one or more research- / audit-interested anaesthetists in every NHS hospital who act as a contact, and in many cases also as the local lead investigator for Health Services Research Centre (HSRC) projects. There is also national network of research and innovation support in the UK NHS, which facilitates research support for eligible studies. As a consequence, in previous HSRC affiliated projects there has been near complete recruitment of eligible UK hospitals [50]. We aim to recruit >95% of eligible NHS hospitals for SNAP 3, but accept that this may be challenging due to the impact of SARS-CoV-2 on workforce and theatre operating.

Patient level:

Our inclusion criteria are deliberately broad, with the intention of including almost all patients who have surgery with a significant physiological stress response that could result in postoperative delirium or morbidity. Our exclusion criteria are limited and aim to minimise recruitment of participants whose clinical course is unlikely to provide information which answers our research questions.

Inclusion criteria:

Patients aged 60 years or older undergoing surgery during the recruitment period are eligible for this study. Surgery includes day-case, emergency, and elective procedures that require general, neuraxial, regional or local anaesthesia.

Exclusion criteria:

We will exclude patients undergoing invasive procedures that are diagnostic or likely to cause minimal physiological stress response, e.g. endoscopy, phacoemulsification, percutaneous tracheostomy insertion. Patients with American Society of Anesthesiologists Physical Status score grade VI are also excluded. See Appendix 1 for examples of included and excluded surgical procedures.

Data collection and follow up procedures for the cohort study

Recruitment for the SNAP 3 observational cohort study will occur over a period (Monday – Friday). The majority of sites are expected to recruit in the main recruitment window in March 2023. Allowance has been made for sites unable to recruit in the March window to recruit within 2 months. If we are unable to achieve our recruitment target, ethical approval has been given for a second recruitment period. Follow up involving direct participant contact will occur up to four months postoperatively. Data linkage with hospital records and ONS death registrations will be carried out at 120 days after discharge and at one, two, five and ten years postoperatively.

1
2
3
4 1
5 2 All sites will use an electronic Case Report Form (CRF) via a secure web-based portal
6 3 'REDCap'. An initial CRF record will be completed for each participant during the study
7 4 week. The CRF includes routinely collected demographics, medical history, surgical
8 5 information, blood laboratory data, SARS-CoV-2 status, surgical risk scores, socioeconomic
9 6 data and frailty assessments. Please see Appendix 2 for details of the data points collected.
10 7

11 8
12 9 There are two active frailty tools that require participant involvement and one passive frailty
13 10 score. The Clinical Frailty Scale (CFS) and the Reported Edmonton Frailty Score (rEFS) are
14 11 both brief and validated methods that do not require specifically trained personnel to
15 12 accurately assess frailty. The electronic Frailty Index (eFI) operationalises the deficit
16 13 accumulation model of frailty but is not available in all areas of the UK. It is calculated from
17 14 Primary Care data. The eFI will be recorded if it has been routinely collected. Those
18 15 carrying out frailty assessments were given details of relevant online training modules [51,
19 16 52]. The conventional cut off values for frailty will be used in analyses. Frailty will be
20 17 identified as CFS ≥ 5 , rEFS ≥ 8 and eFI ≥ 0.25 [28, 53, 54]. The choice of frailty tools aims to
21 18 first, accurately measure frailty in this sample and second, describe the routine usage of
22 19 different frailty tools across the four nations of the UK [53-59].
23 20

24 21
25 22
26 23 Process of care data will be recorded regarding the nature of preoperative assessment,
27 24 anaesthesia type, catheterisation and postoperative care level.
28 25
29 26

30 27
31 28 Multimorbidity is assessed through a list of relevant comorbidities which has been derived
32 29 from the Charlson Comorbidity Index and a priori knowledge of comorbidities relevant to
33 30 older patients with frailty and at risk of delirium [60]. The Elixhauser comorbidity index will
34 31 be calculated from HES data (or equivalent) following the method of Pritchard et al including
35 32 a one-year look back [61].
36 33
37 34

38 35
39 36 Participants who remain inpatients on days three and seven will be assessed for
40 37 postoperative morbidity using an appropriate speciality specific POMS and either the 4AT (if
41 38 not critically ill) or CAM-ICU (if critically ill) [45-48, 62]. Delirium and postoperative
42 39 morbidity will be assumed absent for those discharged alive on the day of surgery.
43 40
44 41

45 42
46 43 Those admitted for one or more nights will have a retrospective notes review to identify
47 44 delirium with the aim of minimising false negatives from researcher assessments alone. This
48 45 will include medical and nursing documentation, from the day of surgery, up to discharge or
49 46 day seven postoperatively, whichever is sooner. A tool has been developed to enable
50 47 objective researcher led retrospective notes evaluation. The tool was developed using DSM-
51 48 5 criteria for a diagnosis of delirium based on literature review and a priori knowledge of
52 49 language used by clinicians to describe delirium [63-68]. . Each diagnostic criterion from
53 50 DSM-5 has been mapped to a set of words and phrases which are commonly used to
54 51 describe that specific clinical feature.
55 52
56 53

57 54
58 55 We aim to minimise the number of missed delirium episodes by combining the findings of
59 56 the notes review and POMS with either the 4AT or CAM-ICU. This pragmatic approach to
60 57 the identification of delirium is proposed due to the inherent difficulty in measuring a
61 58 fluctuating condition with limited resource.
62 59
63 60

1
2
3
4 1
5 2 Quality of life will be assessed via email or telephone follow up at 120 days after surgery.
6 3 The mode of follow up is determined by the participant or their representative. If a
7 4 participant or their representative has opted into both email and telephone follow up but
8 5 does not respond to email, the local investigator will be emailed to prompt a telephone call.
9 6 The EQ-5D-5L and EQ-VAS are validated tools that do not require specific training for
10 7 accurate use [69]. We will also determine the 'days at home' (DAH) and 'days alive and out
11 8 of hospital' (DAOH) at 120 days as a measure of the process of recovery that has been
12 9 shown to be of importance to patients [70]. Days alive and out of hospital is available from
13 10 central records, and hence easier to collect at scale, but excludes time in residential or
14 11 nursing home care, outcomes which are often feared by older patients. Days at home, is
15 12 more difficult to capture, but more closely aligns with what patients want from a good
16 13 recovery. A possible by product of the study is a demonstration of whether the collection of
17 14 DAH is worth the additional research burden.
18
19
20
21
22

23 16 Data linkage via national government held and hospital level datasets will enable us to
24 17 provide more detailed outcome data without further patient or Local Investigator burden.
25 18 We will collaborate with NHS Digital, Digital Health and Care Wales, Electronic Data
26 19 Research and Innovation Service, National Services Scotland and individual Northern Irish
27 20 hospitals to provide as much of the long-term outcome data as possible. Due to individual
28 21 countries differing legislation and record keeping, data obtained will vary across the
29 22 devolved nations.
30
31

32 24 **Data collection for the clinician surveys**

33 25 The organisational survey, S2 will be distributed via email with a direct link to the REDCap
34 26 data entry portal. S3 will be administered by researchers (anaesthetists, physicians or
35 27 research nurses), who will contact medical registrars at the end of an on-call shift. This may
36 28 be done over the telephone or face to face. The researcher will input their answers directly
37 29 into REDCap. There will be no ongoing follow up of clinicians.
38
39

40 31 **Analysis plan**

41 32 Study Cohort:

42 33 Descriptive statistics will be used to describe the basic demographics of our participants and
43 34 key features of our participating sites.
44
45

46 36 Missing Data:

47 37 As with any large study with multiple follow up surveys, there will be missing data. The
48 38 number and proportion of missing observations will be documented in each analysis. For
49 39 each variable, we will assess the likely process that led to missing data, to determine
50 40 whether the data are missing at random or not missing at random. This will determine the
51 41 choice of an appropriate method of dealing with missing data, for example multiple
52 42 imputation.
53
54
55

56 44 Analysis per objective:

57 45 *Objective 1: Estimating the incidences of frailty, multimorbidity and postoperative delirium*

58 46 We will estimate the incidences of our three target variables as the proportion of patients
59 47 living with frailty and /or multimorbidity, and who experience delirium, respectively. We will
60

1
2
3 1 calculate 95 % confidence intervals using the binomial distribution. We will conduct
4 2 sensitivity analyses with inverse probability weights for elective and emergency procedures
5 3 in order to account for the absence of weekend data. We have already obtained estimates
6 4 of the number of emergency and selective procedures carried out at weekends from
7 5 selected hospitals, and will use those to estimate the inverse probability weights.
8
9 6

10 7 *Objective 2 & 3: Bivariate analyses*

11 8 The relationships between frailty, multimorbidity, delirium, primary and secondary
12 9 outcomes will be reported with appropriate models chosen for different outcome types:
13 10 multilevel logistic quantile or linear regression. We will account for clustering of patients in
14 11 hospitals through a random effect for hospitals within mixed-effects models.
15
16 12

17 13 *Objective 4: Multilevel regression models*

18 14 To investigate the relationships between frailty, multimorbidity, delirium and a range of
19 15 outcomes, we will use multilevel regression models adjusting for other clinically relevant
20 16 preoperative patient characteristics and type of surgery, with hospital-level random
21 17 intercepts to control for potential between-hospital differences in outcomes. Appropriate
22 18 models will be chosen for different outcome types: multilevel logistic regression for binary
23 19 outcomes, multilevel quantile regression for length of stay, DAOH and DAH, and multilevel
24 20 linear regression for the EQ-5D utility index. Prior to conducting these analyses, we will draw
25 21 directed acyclic graphs to clarify hypothesized causal relationships and to inform choices of
26 22 potential covariates that should be included, or indeed excluded, from our models.
27
28 23

29 24 *Objective 5: Agreement between frailty tools*

30 25 The analyses for objectives 1-3 will be reported separately for the different frailty measures
31 26 to gauge differences in their performance as predictors of outcome, using a range of
32 27 measures of performance as appropriate for the measurement levels of the various outcomes
33 28 [71]. We won't do the same for the multivariable analyses specified to address objective 4.
34 29 We will measure the pairwise consistency between the three frailty measures using
35 30 Spearman's correlation coefficients. To gauge agreement of clinical judgement in practice, we
36 31 will also assess agreement between dichotomized versions of the three frailty measures,
37 32 using their respective conventional cut-offs. Agreement between dichotomized frailty
38 33 measures will be assessed via percentage agreement and kappa coefficient.
39
40 34

41 35 *Objective 6: Descriptive statistics of interventions*

42 36 To address the objectives relating to hospital-level and patient-level interventions and
43 37 perioperative care designed to address risks associated with patient frailty, we will study the
44 38 sample of patients identified as living with frailty preoperatively and compare them to those
45 39 identified as not frail. We will document between-hospital differences in interventions and
46 40 procedures, using descriptive statistics and graphical methods.
47
48 41

49 42 *Objective 7: Risk prediction model for delirium*

50 43 Development and internal validation of a risk prediction model for delirium will involve the
51 44 following steps: (1) Exploratory and graphical analysis of the shapes of the relationships
52 45 between (numeric) candidate predictors, identified from previous studies and clinical insight,
53 46 and the probability of delirium. (2) Use of fractional polynomials or splines to identify suitable
54 47 transformations of numeric predictors, as appropriate. (3) Penalized logistic regression will
55
56
57
58
59
60

1
2
3 1 be considered for predictor selection, since these have been shown to outperform maximum
4 2 likelihood estimation and backward selection procedures in the development of risk models
5 3 [72]. (4) The discrimination of the risk model will be assessed using the C-statistic (area under
6 4 the ROC curve), which is to be estimated using optimism correction via bootstrapping [73].
7 5 We will also calculate the Brier score and investigate model calibration, using graphical
8 6 displays and the Hosmer-Lemeshow goodness-of-fit statistic. We will follow the TRIPOD
9 7 statement in reporting the development and internal validation of the risk prediction model
10 8 for delirium [74].
11 9

12
13
14 10 *Objective 8: Descriptive statistics of hospital level models of perioperative care*

15 11 The national provision of hospital level perioperative medicine services will be described. The
16 12 description will be sub-divided into care for elective and emergency patients; and degree of
17 13 preoperative and postoperative services.
18 14

19 15 *Objective 9: Associations between in-depth perioperative interventions and outcomes*

20 16 The role of in-depth perioperative interventions in modifying the risk of adverse outcomes in
21 17 patients with frailty will then be assessed using appropriate mixed effects models as for
22 18 objective 4. Patient-level covariates, such as age, socioeconomic status etc. will be included
23 19 as appropriate to distinguish the influence of population characteristics with hospital-level
24 20 perioperative interventions. Although there is inevitably a risk of significant unmeasured
25 21 confounding it is difficult to estimate the direction or magnitude of these effects.
26 22

27 23 *Objective 10: Acute referrals to medicine from older surgical patients*

28 24 Descriptive statistics will be used to describe the number and nature of acute referrals to
29 25 medicine from older surgical patients, and the rate of such referrals by size of hospital
30 26 (determined by number of beds). The nature of the referrals will be reported as resulting in
31 27 a telephone or face to face consultation. Referrals will be categorised by surgical speciality,
32 28 urgency of surgery and primary medical problem.
33 29

34 30 *Objective 11: Identify associations between perioperative medicine services and acute*
35 31 *referrals of older surgical patients to medicine*

36 32 To describe the associations between perioperative medicine services and acute referrals of
37 33 older surgical patients to medicine, we will use mixed effects logistic regression. Patient level
38 34 covariates will be included as appropriate to distinguish the relevant perioperative services.
39 35 Emergency surgery patients will not benefit from an elective perioperative medicine service
40 36 and so will be analysed separately.
41 37

42 38 **Subgroup analyses:**

43 39 Data will be reported according to pre-specified subgroups for objectives 1-6. Exact details
44 40 of subgroups will be finalised once the numbers of patients in potential groups is known. At a
45 41 minimum the following groups will be reported:

- 46 42 • Emergency and elective procedures
- 47 43 • Surgical invasiveness (using the method described by Abbot et al. [75])
- 48 44 • Major surgical specialty (e.g. orthopaedics, gynaecology)
- 49 45 • The 10 most common healthcare resource groups

50 46 Relevant subgroups will be analysed if they include at least 500 participants
51 47

1 Additional analyses and data sharing:

2 Investigators from outside the core study team may wish to conduct secondary analysis of
3 the data from SNAP 3. We recognise the importance of sharing data within the ethical and
4 legal constraints of the original participants' consent, in order to maximise the potential of
5 our dataset. Following a formal request for data sharing, the request will be considered by
6 the SNAP 3 Study Management Group (SMG) and Steering Committee. If the request is
7 made after the relevant groups have been disbanded, then the request will go directly to
8 the Chief Investigator who will consider the request alongside the Executive Management
9 Board of the HSRC.

10
11 There are many potential further analyses possible from the SNAP 3 dataset. We anticipate
12 developing and validating a multimorbidity score for our population. This will then be
13 compared with other measures of multimorbidity to evaluate its ability to predict primary
14 and secondary outcomes. Our secondary analysis plans will continue to evolve as we
15 understand the potential of our cohort's data.

16 **Sample size calculation**

17 Prior to the SARS-CoV-2 pandemic, the estimated achievable sample size for the
18 observational cohort study was around 12,000 participants based on English national data
19 (HES) and previous SNAP projects. We verified that this is a sufficient sample size to achieve
20 the primary and secondary objectives of this study. This estimate has been reduced to
21 8,000, in light of the impact of the pandemic on health services.

22
23
24 To estimate the proportion of patients living with frailty, and the proportion of patients who
25 develop delirium, a sample size of 7,203 is needed for a margin of error of 1 percentage
26 point (width of 95 % confidence interval: 2 percentage points). This calculation is based on
27 an outcome proportion of 0.25, which is a plausible conservative upper bound. The true
28 proportions are likely to be smaller, which would yield greater precision of the estimation of
29 the true proportion.

30
31 To estimate required sample sizes for the delirium risk prediction model, we followed
32 methods published by Riley et al [76]. We made the following assumptions:

- 33 • The number of candidate parameters in the risk prediction model is at most 30
- 34 • The proportion of patients with delirium is at least 0.05, and at most 0.25
- 35 • The Cox-Snell R-square of the prediction model is at least 0.05

36
37 These are conservative assumptions. Using the most conservative assumptions in each
38 calculation, the required sample sizes for the following desirable quality criteria are:

- 39 • Mean absolute error of predicted probabilities ≤ 0.01 : $n = 11,077$
- 40 • Shrinkage during model development using penalized regression methods $\leq 5\%$: $n = 5,395$
- 41 • Overoptimism of model performance $\leq 1\%$: $n = 8,909$

42 These are strict quality criteria, and they suggest that a sample size of around 11,000
43 patients is sufficient to estimate a high-quality clinical prediction model for delirium.

44
45
46 To achieve the objectives relating to hospital variation in, and effects of, processes and
47 procedures for treating patients with frailty, we plan to estimate multivariate mixed effects

1 models. There is no precise method for sample size calculations for these kinds of analyses.
2 A conservative lower bound of the percentage of patients with frailty in our achieved
3 sample is 10 %, which implies a minimum sample size of 1,200 patients with frailty. This will
4 give these analyses meaningful precision even in the presence of many covariates.

5
6 A priori subgroup analyses will be defined in the statistical analysis plan that will be
7 published separately before data-lock.

8 9 **ETHICS AND DISSEMINATION**

10 The study has received the following approvals: Scotland A Research Ethics Committee and
11 Wales Research Ethics Committee 7. Ethical approvals are obtained at national level. Local
12 confirmation of capacity and capability is provided by individual hospitals before study
13 commencement.

14 15 **Patient Consent**

16 All patients who are eligible for SNAP 3 inclusion will have capacity to consent assessed. Those
17 who have capacity to consent to study participation will provide electronic or written consent
18 after being provided with the Participant Information Sheet.

19
20 It is essential to include participants without capacity to consent to study participation in
21 order to minimise sampling bias due to exclusion of the target population. The objectives of
22 SNAP 3 relate directly to patients who have both acute and chronic cognitive impairment.
23 This study is of low participant burden and the new knowledge generated will improve care
24 for those without capacity. We will use the process of consultees (in England, Northern
25 Ireland and Wales) and Personal Legal Representatives (PLR, in Scotland) giving advice or
26 consent respectively.

27
28 Patient participants who lose capacity to consent:

29 We anticipate that a proportion of participants will lose capacity to consent during the
30 study, most commonly due to delirium. Whilst it is vital to continue including these
31 participants to fulfil our research objectives, their continued inclusion is complex, and
32 procedures vary depending on the country.

33 34 *England and Wales:*

35 Those who lose capacity to consent will be treated in accordance with section 34 of the
36 Mental Capacity Act (2005). Information gathered about the participant before loss of
37 capacity will continue to be used in the study. If further interventions are required, then
38 advice will be sought from a consultee for them to continue in the study.

39 40 *Northern Ireland and Scotland:*

41 Those who lose capacity to consent in Northern Ireland will be treated in accordance with
42 section 132 of the Mental Capacity Act (NI 2016). In the event that a previously consenting
43 participant loses capacity, their statement will still stand unless subsequently withdrawn. In
44 Scotland there is no specific legal provision for those who develop incapacity during
45 research studies. It is generally accepted practice to inform those consenting that they will
46 continue to be included in the study even if they develop incapacity.

1
2
3 1 Regardless of capacity, if a participant is distressed by ongoing inclusion in the study then
4 2 they will be withdrawn from the study.
5
6 3

7 4 **Study management**

8 5 The SMG is chaired by the Chief Investigator and meets at least monthly, to direct day to
9 6 day running of the project. The SMG members include those with clinical roles in
10 7 anaesthesia and geriatrics, a statistician, research management and PPI members. The
11 8 Study Steering Committee (SSC) meets at least annually to supervise the conduct of the
12 9 research and its progress achieving the study's objectives whilst working to the
13 10 protocol. We are fortunate to have multidisciplinary input from all interested clinical groups
14 11 and lay representation. We are responsible to the HSRC Executive Management Board. The
15 12 study sponsor is the University of Nottingham.
16
17 13

18 14 **Patients and public involvement**

19 15 The topic for SNAP 3 was selected through a competitive process of submissions open to all
20 16 anaesthetists across the UK. The panel for project selection included representatives from
21 17 patient and public involvement (PPI) groups, Royal College of Anaesthetists staff, clinicians
22 18 and trainees.
23
24 19

25 20 Our PPI members have provided valuable input into the design and conduct of the study via
26 21 the SMG and the SSC. They have been influential in the selection of outcome measures
27 22 especially relating to quality of life. Our PPI members have directly contributed to the
28 23 format and wording of the patient facing documentation and communication with sites.
29 24 They have also provided guidance on the acceptability of our study design in relation to
30 25 participant burden. PPI members will be involved in the publication of our results through
31 26 our dissemination plans and the production of future public facing documents.
32
33 27

34 28 **Dissemination**

35 29 We intend to present the results via our website (hosted by the HSRC), in peer reviewed
36 30 journals and through conference presentations. We will provide relevant summary reports
37 31 for the following groups:

- 38 32 1. Our participants- participants will be offered the opportunity to receive summary
39 33 findings up to three years after recruitment.
- 40 34 2. Our recruiting sites- all sites can receive an overall summary and can request a
41 35 hospital specific summary.
- 42 36 3. Healthcare policy makers- this will include medical and nursing royal colleges,
43 37 specialist societies, Department of Health, NHS England, NHS Wales, NHS Scotland
44 38 and Health and Social Care Ireland.
- 45 39 4. The public- relevant patient groups and charities will be informed of our results with
46 40 the assistance of our PPI members.
- 47 41 5. Participating NHS Trusts and Health Boards- all NHS Chief Executives will receive a
48 42 summary of the key findings.
49 43

50 44 All collaborators who recruit or collect data from participants, or complete clinician surveys
51 45 will be acknowledged in the manuscripts that arise from this study. Full details can be
52 46 obtained on our website.
53
54 47
55
56
57
58
59
60

ACKNOWLEDGEMENTS

We would like to acknowledge the hard work and enthusiasm of all of our Local Investigators, Trainee Principal Investigators, Principal Investigators, and the wider SNAP 3 Project Team. We are grateful to the Research and Audit Federation of Anaesthetic Trainees and their local networks for their support of the study.

CONTRIBUTOR STATEMENT

IM initiated the collaborative project; is guarantor; the grant holder; revised the draft paper; cowrote the analysis plan and is analysing the data. CS obtained ethical approval; implemented the study in the UK; designed the data collection tools; monitored data collection for the study; cowrote the statistical analysis plan; cleaned and is analysing the data; and drafted and revised the paper. PM provided statistical expertise in study design and cowrote the analysis plan. JP provided expertise in geriatric medicine; designed data collection tools and revised the draft paper. TP implemented the study in Australia; designed data collection tools and revised the draft paper.

COMPETING INTERESTS

The authors declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

COLLABORATORS: SNAP 3 Project Team: Laura Cortes, Bob Evans, Carol Green, Jose Lourtie, Akshay Shah, Christine Taylor, Karen Williams

FUNDING STATEMENT

The study is generously funded by Royal College of Anaesthetists and the independent charity, the Frances and Augustus Newman Foundation. We are fortunate to receive support from the National Institute for Health Research Clinical Research Network. Neither of the funders have influenced the design or conduct of the study.

DATA STATEMENT

The data from the SNAP 3 study will be published in a data repository.

REFERENCES

1. Fowler AJ, Abbott TEF, Prowle J, et al. Age of patients undergoing surgery. *Br J Surg*. 2019;106(8):1012-8.
2. Whitaker M HJ, Brownsell A. Access All Ages. Royal College of Surgeons; 2012.
3. Lin HS, Watts JN, Peel NM, et al. Frailty and post-operative outcomes in older surgical patients: a systematic review. *BMC Geriatr*. 2016;16(1):157.
4. Simon HL, Reif de Paula T, Profeta da Luz MM, et al. Frailty in older patients undergoing emergency colorectal surgery: USA National Surgical Quality Improvement Program analysis. *Br J Surg*. 2020;107(10):1363-71.

- 1 5. Thillainadesan J, Mudge AM, Aitken SJ, et al. The Prognostic Performance of Frailty
2 for Delirium and Functional Decline in Vascular Surgery Patients. *J Am Geriatr Soc.*
3 2021;69(3):688-95.
- 4 6. Van de Ree CLP, Landers MJF, Kruithof N, et al. Effect of frailty on quality of life in
5 elderly patients after hip fracture: a longitudinal study. *BMJ Open.* 2019;9(7):e025941.
- 6 7. Aitken RM, Partridge JSL, Oliver CM, et al. Older patients undergoing emergency
7 laparotomy: observations from the National Emergency Laparotomy Audit (NELA) years 1-4.
8 *Age Ageing.* 2020;49(4):656-63.
- 9 8. Eamer G, Taheri A, Chen SS, et al. Comprehensive geriatric assessment for older
10 people admitted to a surgical service. *Cochrane Database of Systematic Reviews.* 2018(1).
- 11 9. Oliver CM, Bassett MG, Poulton TE, et al. Organisational factors and mortality after
12 an emergency laparotomy: multilevel analysis of 39 903 National Emergency Laparotomy
13 Audit patients. *Br J Anaesth.* 2018;121(6):1346-56.
- 14 10. Shipway D, Koizia L, Winterkorn N, et al. Embedded geriatric surgical liaison is
15 associated with reduced inpatient length of stay in older patients admitted for
16 gastrointestinal surgery. *Future Healthc J.* 2018;5(2):108-16.
- 17 11. Thu K, Nguyen HPT, Gogulan T, et al. Care of Older People in Surgery for general
18 surgery: a single centre experience. *ANZ J Surg.* 2021;91(5):890-5.
- 19 12. Morris EJ, Taylor EF, Thomas JD, et al. Thirty-day postoperative mortality after
20 colorectal cancer surgery in England. *Gut.* 2011;60(6):806-13.
- 21 13. Schweigert M, Solymosi N, Dubecz A, et al. Surgery for parapneumonic pleural
22 empyema--What influence does the rising prevalence of multimorbidity and advanced age
23 has on the current outcome? *Surgeon.* 2016;14(2):69-75.
- 24 14. Partridge JSL, Harari D, Martin F, et al. Randomized clinical trial of comprehensive
25 geriatric assessment and optimization in vascular surgery. *Br J Surg.* 2017;104(6):679-87.
- 26 15. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *Lancet.* 2013;381(9868):752-
27 62.
- 28 16. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and
29 implications for health care, research, and medical education: a cross-sectional study.
30 *Lancet.* 2012;380(9836):37-43.
- 31 17. Hewitt J, McCormack C, Tay HS, et al. Prevalence of multimorbidity and its
32 association with outcomes in older emergency general surgical patients: an observational
33 study. *BMJ Open.* 2016;6(3):e010126.
- 34 18. American Psychiatric A. *Diagnostic and Statistical Manual of Mental Disorders (DSM-
35 5®).* Washington, UNITED STATES: American Psychiatric Publishing; 2013.
- 36 19. Inouye SK, Bogardus ST, Jr., Charpentier PA, et al. A multicomponent intervention to
37 prevent delirium in hospitalized older patients. *N Engl J Med.* 1999;340(9):669-76.
- 38 20. Wang YY, Yue JR, Xie DM, et al. Effect of the Tailored, Family-Involved Hospital Elder
39 Life Program on Postoperative Delirium and Function in Older Adults: A Randomized Clinical
40 Trial. *JAMA Intern Med.* 2019.
- 41 21. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. *Lancet.*
42 2014;383(9920):911-22.
- 43 22. McCusker J, Cole MG, Dendukuri N, et al. Does delirium increase hospital stay? *J Am
44 Geriatr Soc.* 2003;51(11):1539-46.
- 45 23. Teale E, Young J. Multicomponent delirium prevention: not as effective as NICE
46 suggest? *Age and Ageing.* 2015;44(6):915-7.

- 1 24. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *The Lancet*.
2 2013;381(9868):752-62.
- 3 25. Verloo H, Goulet C, Morin D, et al. Association between frailty and delirium in older
4 adult patients discharged from hospital. *Clin Interv Aging*. 2016;11:55-63.
- 5 26. Thillainadesan J, Aitken SJ, Monaro SR, et al. Geriatric Comanagement of Older
6 Vascular Surgery Inpatients Reduces Hospital-Acquired Geriatric Syndromes. *J Am Med Dir
7 Assoc*. 2022;23(4):589-95 e6.
- 8 27. Cizginer S, Marcantonio E, Vasunilashorn S, et al. The Cognitive Reserve Model in the
9 Development of Delirium: The Successful Aging After Elective Surgery Study. *J Geriatr
10 Psychiatry Neurol*. 2017;30(6):337-45.
- 11 28. Group FGW. Guideline for Perioperative Care for People Living with Frailty
12 Undergoing Elective and Emergency Surgery. Centre for Perioperative Care and the British
13 Geriatrics Society; 2021 22/09/21. Contract No.: 1.0.
- 14 29. Leiner T, Nemeth D, Hegyi P, et al. Frailty and Emergency Surgery: Results of a
15 Systematic Review and Meta-Analysis. *Front Med (Lausanne)*. 2022;9:811524.
- 16 30. Panayi AC, Orkaby AR, Sakthivel D, et al. Impact of frailty on outcomes in surgical
17 patients: A systematic review and meta-analysis. *Am J Surg*. 2019;218(2):393-400.
- 18 31. Sündermann S, Dademasch A, Rastan A, et al. One-year follow-up of patients
19 undergoing elective cardiac surgery assessed with the Comprehensive Assessment of Frailty
20 test and its simplified form☆. *Interactive CardioVascular and Thoracic Surgery*.
21 2011;13(2):119-23.
- 22 32. Patel KV, Brennan KL, Brennan ML, et al. Association of a modified frailty index with
23 mortality after femoral neck fracture in patients aged 60 years and older. *Clin Orthop Relat
24 Res*. 2014;472(3):1010-7.
- 25 33. Ommundsen N, Wyller TB, Nesbakken A, et al. Frailty Is an Independent Predictor of
26 Survival in Older Patients With Colorectal Cancer. *The Oncologist*. 2014;19(12):1268-75.
- 27 34. Green P, Woglom AE, Genereux P, et al. The Impact of Frailty Status on Survival After
28 Transcatheter Aortic Valve Replacement in Older Adults With Severe Aortic Stenosis: A
29 Single-Center Experience. *JACC: Cardiovascular Interventions*. 2012;5(9):974-81.
- 30 35. Hewitt J, Moug SJ, Middleton M, et al. Prevalence of frailty and its association with
31 mortality in general surgery. *Am J Surg*. 2015;209(2):254-9.
- 32 36. Ambler GK, Brooks DE, Al Zuhir N, et al. Effect of frailty on short- and mid-term
33 outcomes in vascular surgical patients. *British Journal of Surgery*. 2015;102(6):638-45.
- 34 37. Kistler EA, Nicholas JA, Kates SL, et al. Frailty and Short-Term Outcomes in Patients
35 With Hip Fracture. *Geriatr Orthop Surg Rehabil*. 2015;6(3):209-14.
- 36 38. Lees NP, Peden CJ, Dhesei JK, et al. *The High Risk General Surgical Patient: Raising the
37 Standard*. London: Royal College of Surgeons; 2018.
- 38 39. Needham MJ, Webb CE, Bryden DC. Postoperative cognitive dysfunction and
39 dementia: what we need to know and do. *Br J Anaesth*. 2017;119(suppl_1):i115-i25.
- 40 40. Anaesthetists RCo. Guidelines for the Provision of Anaesthesia Services for the
41 Perioperative Care of Elective and Urgent Care Patients 2022. Royal College of Anaesthetists
42 Website- Guidelines for the Provision of Anaesthesia Services: Royal College of
43 Anaesthetists; 2022. Contract No.: Chapter 2.
- 44 41. Braude P, Partridge JS, Shipway D, et al. Perioperative medicine for older patients:
45 how do we deliver quality care? *Future Hosp J*. 2016;3(1):33-6.
- 46 42. Donabedian A. Evaluating the Quality of Medical Care. *The Milbank Memorial Fund
47 Quarterly*. 1966;44(3):166-206.

- 1 43. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for
2 rapid delirium screening: a study in 234 hospitalised older people. *Age Ageing*.
3 2014;43(4):496-502.
- 4 44. MacLulich AM, Shenkin SD, Goodacre S, et al. The 4 'A's test for detecting delirium in
5 acute medical patients: a diagnostic accuracy study. *Health Technol Assess*. 2019;23(40):1-
6 194.
- 7 45. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients:
8 validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit*
9 *Care Med*. 2001;29(7):1370-9.
- 10 46. Grocott MP, Browne JP, Van der Meulen J, et al. The Postoperative Morbidity Survey
11 was validated and used to describe morbidity after major surgery. *J Clin Epidemiol*.
12 2007;60(9):919-28.
- 13 47. Marufu TC, Elphick HL, Ahmed FB, et al. Short-term morbidity factors associated with
14 length of hospital stay (LOS): Development and validation of a Hip Fracture specific
15 postoperative morbidity survey (HF-POMS). *Injury*. 2019;50(4):931-8.
- 16 48. Sanders J, Keogh BE, Van der Meulen J, et al. The development of a postoperative
17 morbidity score to assess total morbidity burden after cardiac surgery. *J Clin Epidemiol*.
18 2012;65(4):423-33.
- 19 49. Foundation ER. EQ-5D-5L User
20 Guide. EuroQol Research Foundation, Marten Meesweg 107, 3068 AV Rotterdam, The
21 Netherlands; 2019.
- 22 50. Moonesinghe SR, Wong DJN, Farmer L, et al. SNAP-2 EPICCS: the second Sprint
23 National Anaesthesia Project-EPIdeMiology of Critical Care after Surgery: protocol for an
24 international observational cohort study. *BMJ Open*. 2017;7(9):e017690.
- 25 51. Mclsaac DI, Group. AR. Clinical Frailty Scale (CFS) Training Module Articulate: The
26 Ottawa Hospital; 2019 [Available from:
27 <https://rise.articulate.com/share/deb4rT02lvONbq4AfcMNRUudcd6QMts3#/>].
- 28 52. Mclsaac DI, Group. AR. Edmonton Frail Scale Training Course Articulate: The Ottawa
29 Hospital; 2019 [Available from:
30 <https://rise.articulate.com/share/EM4TimhmYi0V9MpZCGebkTvn9hkmpx-X#/>].
- 31 53. Aucoin SD, Hao M, Sohi R, et al. Accuracy and Feasibility of Clinically Applied Frailty
32 Instruments before Surgery: A Systematic Review and Meta-analysis. *Anesthesiology*.
33 2020;133(1):78-95.
- 34 54. Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty
35 index using routine primary care electronic health record data. *Age Ageing*. 2016;45(3):353-
36 60.
- 37 55. Haren A, Lal R, Walker D, et al. Frailty assessment in older urological patients prior to
38 surgery: a systematic review and narrative synthesis. *Ther Adv Urol*.
39 2020;12:1756287220916614.
- 40 56. Partridge JS, Harari D, Dhesei JK. Frailty in the older surgical patient: a review. *Age*
41 *Ageing*. 2012;41(2):142-7.
- 42 57. Rolfson DB, Majumdar SR, Tsuyuki RT, et al. Validity and reliability of the Edmonton
43 Frail Scale. *Age Ageing*. 2006;35(5):526-9.
- 44 58. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and
45 frailty in elderly people. *CMAJ*. 2005;173(5):489-95.
- 46 59. Hilmer SN, Perera V, Mitchell S, et al. The assessment of frailty in older people in
47 acute care. *Australasian Journal on Ageing*. 2009;28(4):182-8.

- 1 60. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic
2 comorbidity in longitudinal studies: development and validation. *J Chronic Dis.*
3 1987;40(5):373-83.
- 4 61. Pritchard E, Fawcett N, Quan TP, et al. Combining Charlson and Elixhauser scores
5 with varying lookback predicated mortality better than using individual scores. *J Clin*
6 *Epidemiol.* 2021;130:32-41.
- 7 62. Jeong E, Park J, Lee J. Diagnostic Test Accuracy of the 4AT for Delirium Detection: A
8 Systematic Review and Meta-Analysis. *Int J Environ Res Public Health.* 2020;17(20).
- 9 63. Geriatric Medicine Research C. Retrospective delirium ascertainment from case
10 notes: a retrospective cohort study. *BMJ Open.* 2021;11(5):e042440.
- 11 64. Saczynski JS, Kosar CM, Xu G, et al. A tale of two methods: chart and interview
12 methods for identifying delirium. *J Am Geriatr Soc.* 2014;62(3):518-24.
- 13 65. Puelle MR, Kosar CM, Xu G, et al. The Language of Delirium: Keywords for Identifying
14 Delirium from Medical Records. *J Gerontol Nurs.* 2015;41(8):34-42.
- 15 66. Morandi A, Solberg LM, Habermann R, et al. Documentation and management of
16 words associated with delirium among elderly patients in postacute care: a pilot
17 investigation. *J Am Med Dir Assoc.* 2009;10(5):330-4.
- 18 67. Kuhn E, Du X, McGrath K, et al. Validation of a consensus method for identifying
19 delirium from hospital records. *PLoS One.* 2014;9(11):e111823.
- 20 68. Inouye SK, Leo-Summers L, Zhang Y, et al. A Chart-Based Method for Identification of
21 Delirium: Validation Compared with Interviewer Ratings Using the Confusion Assessment
22 Method. *Journal of the American Geriatrics Society.* 2005;53(2):312-8.
- 23 69. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of
24 life. *Health Policy.* 1990;16(3):199-208.
- 25 70. Jerath A, Austin PC, Wijeyesundera DN. Days Alive and Out of Hospital: Validation of a
26 Patient-centered Outcome for Perioperative Medicine. *Anesthesiology.* 2019;131(1):84-93.
- 27 71. Grudzinski AL, Aucoin S, Talarico R, et al. Comparing the predictive accuracy of frailty
28 instruments applied to preoperative electronic health data for adults undergoing noncardiac
29 surgery. *British Journal of Anaesthesia.* 2022;129(4):506-14.
- 30 72. Van Smeden M, Moons KG, de Groot JA, et al. Sample size for binary logistic
31 prediction models: Beyond events per variable criteria. *Stat Methods Med Res.*
32 2019;28(8):2455-74.
- 33 73. Austin PC, Steyerberg EW. Events per variable (EPV) and the relative performance of
34 different strategies for estimating the out-of-sample validity of logistic regression models.
35 *Stat Methods Med Res.* 2017;26(2):796-808.
- 36 74. Collins GS, Reitsma JB, Altman DG, et al. Transparent Reporting of a multivariable
37 prediction model for Individual Prognosis Or Diagnosis (TRIPOD). *Ann Intern Med.*
38 2015;162(10):735-6.
- 39 75. Abbott TEF, Fowler AJ, Dobbs TD, et al. Frequency of surgical treatment and related
40 hospital procedures in the UK: a national ecological study using hospital episode statistics.
41 *Br J Anaesth.* 2017;119(2):249-57.
- 42 76. Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing
43 a clinical prediction model. *BMJ.* 2020;368:m441.

Appendix 1: SNAP 3 Examples of Included and Excluded Procedures

This list contains examples of included and excluded procedures for SNAP 3. We hope that it will be useful when making decisions regarding whether a participant should be approached for the study. It is not designed to be comprehensive, most surgical procedures are included. We have tried to not include the very minor procedures but it is challenging to know where to draw the line. We hope this guidance is useful.

Ophthalmology

Include	Exclude
Corneal grafts	Any procedure under topical anaesthesia
Scleral buckle	LASER (cornea, medical retina)
Eyelid reconstruction	Adnexal (eyelid surgery inc. ptosis, blepharoplasty)
Keratoplasty	Removal of oil from vitreous body
Excision of scalp/skin lesions if require a split skin graft (SSG) or flap	Excision of scalp/skin lesions not requiring a SSG or flap
Vitreoretinal surgery	Superficial eye lid surgery
Strabismus surgery	Vitrectomy using pars plana approach
Enucleation/eviscerations/orbital decompression	Correction of entropion of lower eyelid
Radioactive plaque insertion & removal	Dacryocystorhinostomy
Tantalum markers	Cataract surgery
Glaucoma surgery	Removal of sutures
Anterior orbitotomy	Needling
Trabeculectomy	Preserflo microshunt & mitomycin-C
Retinal surgery anaesthesia	Cataract surgery (regardless of anaesthesia mode)

General Surgery

Include	Exclude
Inguinal hernia repair under local anaesthesia +/- sedation	Lymph node biopsy
VAC dressing change	Simple dressing change
Perianal excision of rectal polyp	Diagnostic and therapeutic endoscopy regardless of anaesthesia mode
EUA rectum	
Manual evacuation	
Axillary clearance	
Oesophageal dilation/stenting	

ENT

Include	Exclude
Excision of larger lesions e.g basal cell carcinoma (BCC)/squamous cell carcinoma (SCC) e.g. requiring more than primary closure, SSG/flap. NB. Mode of anaesthetic here does not influence decision	Excision of smaller BCC/SCC e.g. no SSG/flap required. NB. Mode of anaesthetic here does not influence decision
Microlaryngoscopy	Biopsy of tongue
Minimally invasive parathyroidectomy	Frenuloplasty
Manipulation or examination under anaesthetic nose	Removal salivary tube
Cervical lymph node biopsy if GA	Tracheostomy insertion/change
Panendoscopy	Grommets
	Anaesthesia for diagnostic procedures
	Tracheo-oesophageal puncture
	Thyroplasties
	Tracheostomy insertion/change

Thoracics

Include	Exclude
Diagnostic bronchoscopy if with other procedure	Endobronchial ultrasound (EBUS)
Tracheal stenting	Diagnostic bronchoscopy alone
Rigid bronchoscopy	Diagnostic and therapeutic bronchoscopy/pleuroscopy
Mediastinoscopy	Chest drain as sole procedure
Video assisted thoracoscopic surgery (VATS)	
Endoscopic procedures performed ancillary to surgical procedure o Bronchoscopy prior to lung resection	

Cardiac

Include	Exclude
Transcatheter aortic valve implantation (TAVI)	Ablations
Other minimally invasive valve replacement procedures carried out under general anaesthesia	PPM lead extractions
	Angiography, percutaneous coronary intervention (PCI)

	Insertion of permanent pacemaker (PPM) / implantable cardioverter defibrillator (ICD)
	Cardioversion
	Electrophysiology (diagnostic or therapeutic)
	Insertion of intra-aortic balloon pump (IABP)

Hands

Include	Exclude
	Carpal tunnel decompression under local anaesthetic
	Dupuytren's palmar fasciectomy
	Trigger finger release
	Excision of hand lesion if small

Trauma & Orthopaedics Emergency Department

Include	Exclude
Ulnar nerve transposition	Aspiration of knee under local anaesthetic
Removal of metal work	Cheilectomy
Excision of olecranon bursa	Trigger point injections
Vertebroplasty	Therapeutic epidural injection
Trapeziectomy	Intra-articular joint injections
Knee replacement	Dupuytren's fasciectomy
Osteotomy of any bone	MUA joint
Replacement of hip joint	MUA fracture in ED
Replacement of shoulder joint	General anaesthesia/sedation for scanning/ICU management only
Small joint fusion	Post-arrest management
Insertion K wire	Erector spinae catheters
MUA fracture in theatre	Joint injections
Surgery for trauma	Joint aspiration
MUA fractures/dislocations in theatre	
Joint washout	

Urology

Include	Exclude
Rigid cystoscopy	Flexible cystoscopy
Urethral dilatation	Circumcision under local anaesthetic
Transurethral resection of bladder tumour	Standard circumcision under general anaesthetic
Transurethral resection of prostate	Transperineal prostate biopsy

Hydrocele under general anaesthetic	Flexible ureteroscopy
Laser fragmentation of stone	Cystoscopy under local anaesthesia
Nephrostomy	Prostate brachytherapy
TURP/TURBT	
Rigid diagnostic/surveillance cystoscopy	
Stent change	

Vascular

Include	Exclude
Fistula ligation and banding	Varicose veins under local anaesthetic
Fistula creation	
Endovascular aneurysm repair (EVAR)	

Interventional Radiology

Include	Exclude
EVAR	CT guided biopsies
Angioplasty	IV access/line insertion
CT guided drain	Endoscopic retrograde cholangiopancreatography (ERCP)

Dental

Include	Exclude
Extractions	

Gynaecology

Include	Exclude
Therapeutic hysteroscopy	Diagnostic hysteroscopy +/- biopsy
Laparoscopic hysterectomy	Hysteroscopy and smear
Cervical polypectomy	

Neurosurgery

Include	Exclude
Sympathetic nerve stimulator insertion or removal	SNS battery or lead change
Spinal cord stimulator insertion	SNS reprogramming
	SCS trial if purely percutaneous

Appendix 2: SNAP 3 Case Report Form

Below are the questions used in REDCap for the SNAP 3 study. For brevity, previously published, validated tools have not been replicated in this document. References for tools used in the SNAP 3 study can be found in the reference list of our accompanying paper.

1.0	Participant details				
1.1	Which country is your hospital based in?	England	Northern Ireland	Scotland	Wales
1.2	Which hospital site are you completing this form for?				
1.3	Is the potential participant having surgery AND 60 years or above?	Yes		No	
1.4	What is the planned date of surgery?				
1.5	Does the potential participant have the capacity to consent?				
1.6	Is there a consultee/Personal Legal Representative (PLR) to offer advice? This may be face to face or over the telephone.	Yes		No	
1.7	Is the participant's Consultee (England, Wales and Northern Ireland) or Personal Legal Representative (Scotland) available in person or over the telephone?	Yes		No	
1.8	Participant first name				
1.9	Participant surname				
1.10	Participant date of birth				
1.11	Participant NHS/CHI/H&C number				
1.12	Would the participant/Consultee/PLR be able to complete a survey at 4 months by email or telephone?	Yes by email	Yes by telephone	No	
1.13	Email address				
1.14	Telephone number				

2.0 Frailty assessment					
2.1	At any point during the participant's clinical pathway, were they assessed for frailty?	Yes		No	
2.2	Which frailty tool was used to assess the participant?	Clinical Frailty Scale /Rockwood Frailty Scale	Edmonton Frailty Scale (scored out of 17)	Reported Edmonton Frail Scale (scored out of 18)	Groningen Frailty Indicator
		Gait Speed Test	PRISMA-7	Risk Analysis Index-C	Timed Up and Go (TUG) Test
		Electronic Frailty Index	Hospital Risk Frailty Index	Grip Strength	Comprehensive Geriatric Assessment
2.3	What was the result of the frailty tool?				
2.4	Clinical Frail Scale (as completed by the clinical or research team)	1-9			
2.5	Reported Edmonton Frail Scale (as completed by the clinical or research team)	0-18			
2.6	Electronic frailty index	0-36			
3.0 Demographics and ADLs					
3.1	Postcode				
3.2	Ethnic group	Census categories			
3.3	Highest level of education	Degree level eg. degree, NVQ Level 4-5, Higher National Certificate, Higher National Diploma, BTEC Higher Level, professional	2+ A levels/VCEs, 4+ AS Levels, Higher School Certificate, NVQ Level 3, Advanced GNVQ, City and Guilds Advanced Craft, BTEC National, Scottish Higher	Apprenticeship	5 or more O Levels (passes)/CSEs (grade 1), School Certificate, 1 A Level, 2-3 AS Levels/VCEs, NVQ Level 2, Intermediate GNVQ, City and Guilds Craft, BTEC, Scottish Higher,

		qualifications (eg. teaching or nursing) or other equivalent higher education qualifications	National Diploma, Scottish Higher National Certificate, SVQ level 4+) or equivalent		Scottish Advanced Higher or equivalent qualifications
		O levels/CSEs (any grade), Foundation Diploma, NVQ level 1, Foundation GNVQ, O grade, Scottish Standard Grade or equivalent qualifications	No formal qualifications	Don't know	
3.4	Biological sex	Female		Male	
3.5	Weight				
3.6	Height				
3.7	BMI				
3.8	Source of admission	Own home	Sheltered housing, retirement complex	Residential home	Nursing home
		Rehabilitation facility (inpatient community unit or care home with the purpose of short term rehabilitation)	Homeless	Another secondary care hospital	Other, please specify

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29	3.9	Help with activities of daily living (ADLs)	No, the participant receives no help with ADLs or the participant has help for lifestyle reasons only (would easily be able to do the tasks if needed).	Needs help with any of the following: transportation, shopping, managing finances, shopping, meal preparation, house cleaning, managing communication with others, managing medications	Needs help with any of the following: ambulating, feeding, dressing, personal hygiene, continence, toileting.	
30	4.0 Preoperative assessment					
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	4.1	How was the participant assessed preoperatively?	Nurse (or AHP) led assessment on day of surgery only	Anaesthetist led assessment on day of surgery only	Nurse (or AHP) led clinic	Anaesthetist led clinic
48 49 50 51 52 53 54 55 56 57 58 59 60			Physician (non geriatrician) led clinic	Geriatrician led clinic	MDT clinic	Other
			None of the above			
	4.2	Urgency of surgery as per NCEPOD criteria	Emergency	Urgent	Expedited	Planned
	4.3	Indication for surgery	Confirmed cancer	Possible cancer e.g. surgery with the aim of diagnosing possible cancer	Non-cancer	
	4.4		ASA I	ASA II	ASA III	ASA IV

	Which ASA score would you give the participant?	ASA V			
4.5	Surgical Outcome Risk Tool (SORT) Version 2 (including procedure type and surgical speciality, as completed by the clinical or research team)				
5.0 Comorbidities					
5.1	Does the participant have any of the following comorbidities?	MI (history of MI based on patient history, notes, history of stent	Heart failure (dyspnoea that has responded to heart failure treatment)	AF (paroxysmal/permanent AF, not if successfully ablated)	Valvular heart disease
		Hypertension (even if treated, do not include those with one isolated episode)	Peripheral vascular disease (treated and untreated)	COPD (probable clinical diagnosis)	Other chronic lung disease
		OSA/obesity hypoventilation syndrome (symptomatic, not purely positive STOP-BANG)	Cerebrovascular disease with mild or no residual symptoms (includes TIA, intracerebral/subarachnoid haemorrhage and stroke diagnosed on CT with no symptoms)	Hemiplegia or paraplegia (from any cause)	Dementia
		Mild cognitive	Anxiety or depression	Parkinson's disease	Diabetes (not just

		impairment	(on treatment)	or parkinsonism	impaired glucose tolerance or if in remission)
		Moderate or severe renal disease (acute or chronic, stage 3A+, eGFR< 60)	Benign prostatic hypertrophy (can be self reported)	Liver disease (with or without portal hypertension)	Peptic ulcer disease (even if treated and not symptomatic)
		Malignancy	Lymphoma (of any type, acute or chronic)	Leukaemia (of any type, acute or chronic)	Connective tissue/rheumatological disease (systemic lupus erythematosus, polymyositis, mixed connective tissue disease, polymyalgia rheumatica, psoriatic arthropathy or rheumatoid arthritis)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		Osteoarthritis (include self reported)	AIDS	Hearing impairment (uses hearing aids or struggles to manage a conversation at usual volumes of speech)	Visual impairment (registered partially sighted)
5.2	Does the participant have complications from their diabetes?	Diabetes without chronic complication		Diabetes with chronic complication	
5.3	How severe is the participant's liver disease?	Mild liver disease (without portal hypertension)		Moderate or severe liver disease (with portal hypertension)	
5.4	Which type(s) of malignancy does the participant have/has had?	Any solid malignancy without metastases		Metastatic solid tumour	
5.5	When was participant's malignancy/malignancies first diagnosed?	≤ 5 years ago		> 5 years ago	
6.0	Investigations within 12 weeks				
6.1	Haemoglobin g/L				
6.2	White cell count 10 ⁹ /L				
6.3	Neutrophil 10 ⁹ /L				
6.4	Lymphocyte 10 ⁹ /L				
6.5	Sodium mmol/L				
6.6	Potassium mmol/L				
6.7	Creatinine micromol/L				
6.8	eGFR ml/min/1.73 ²				

6.9	What is the participant's SARS-Cov-2 status preoperatively?	Tested positive or not tested and treated as positive	Tested negative or not tested and treated as negative	Don't know	
7.0 Day of procedure					
7.1	Date of operation				
7.2	Type of anaesthesia	General anaesthesia with volatiles	General anaesthesia with total intravenous anaesthesia (TIVA)	Neuraxial	Regional
		Sedation	Local infiltration	Don't know	
7.3	Was the participant catheterised?	No	Long-term/pre-admission catheter	Electively catheterised pre/intra-op	Catheterised post-op
7.4	What level of care did the participant receive postoperatively (on the day of surgery)?	Ward (level 0 or 1 care, including day case units)	Unplanned admission to PACU or equivalent (level 1.5 care)	Unplanned admission to PACU or equivalent (level 2/3 care)	Unplanned critical care admission (level 2 or 3 care)
		Planned admission to PACU or equivalent (level 1.5 care)	Planned admission to PACU or equivalent (level 2/3 care)	Planned critical care admission (level 2 or 3 care)	Don't know
7.5	Was the participant a day case patient who has been successfully discharged?	Yes, they have been discharged on the day of surgery	No, they are planned to be an inpatient OR they were intended to be day case but haven't been	Don't know	

			discharged on the day of surgery		
8.0	Day 3 follow up				
8.1	Postoperative Morbidity Survey (general/cardiac/fractured neck of femur, as completed by the research team)				
8.2	Documented new confusion or delirium	Yes	No		
8.3	4AT (if the participant isn't critically unwell, as completed by the clinical or research team)	0-12			
8.4	CAM-ICU (if the participant is critically unwell, as completed by the clinical or research team)	Negative		Positive	
8.5	Does the participant recall any symptoms of postoperative delirium or 'acute confusion'?	Yes		No	
9.0	Day 7 follow up				
9.1	Postoperative Morbidity Survey (general/cardiac/fractured neck of femur, as completed by the research team)				
9.2	Documented new confusion or delirium	Yes	No		
9.3	4AT (if the participant isn't critically unwell, as completed by the clinical or research team)	0-12			
9.4	CAM-ICU (if the participant is critically unwell, as completed by the clinical or research team)	Negative		Positive	
9.5	Does the participant recall any symptoms of	Yes		No	

	postoperative delirium or 'acute confusion'?				
10.0	Delirium notes review				
	<p>SNAP 3 will use the validated 4AT and CAM-ICU to detect delirium in participants postoperatively. Due to its fluctuating nature, some participants will not be experiencing delirium at the time of their follow up even though they have had delirium. We would like to maximise the likelihood of detecting delirium by undertaking a notes review on day seven in addition to the validated assessment tools.</p> <p>The notes review will provide the study with an impression of whether or not a patient experienced delirium outside of the time of their delirium assessment. Based on existing literature, a notes review is more likely to detect delirium which occurs at night and hyperactive delirium, than a single assessment (such as CAM) alone. The diagnosis of delirium is often not clearly documented in patient's notes. Estimates of previously unrecognised delirium from retrospective notes are variable, ranging from 7-43%. Nursing notes are more likely than medical notes to document the presence of keywords indicating delirium.</p> <p>The use of DSM-V criteria expanded with words describing delirium have been selected based on previous literature and a priori knowledge. Please review the nursing and medical notes as below. Only record evidence from (up to and including) day seven postoperatively. If there is evidence of delirium occurring on day eight, then please do not report this. If you believe that you have identified a current diagnosis of unrecognised delirium from the notes then please pass these concerns to the clinical team. This is a requirement of good clinical and research practice.</p>				
10.1	If the participant has a diagnosis of delirium documented either using a validated tool or as free text documentation of 'delirium' or 'delirious', then please select 'Positive diagnosis of delirium'	Positive diagnosis of delirium	No explicit diagnosis of delirium	Don't know	
	The following questions summarise the DSM-V criteria for the diagnosis of delirium and give examples of words frequently used to describe delirium in the clinical notes.				
10.2	<p><u>DSM criteria A:</u> Is there any documentation of the following? Inattention, inattentive, distractable Muddled Drowsy, drowsiness</p>	Yes, phrases similar to the ones listed are used in the notes	No	Don't know	

	Unrousable, unresponsive Hypoactive Agitated, agitation Altered mental status Inability to count from 20-1 Inability to recite months of the year backwards				
10.3	DSM criteria B: Is there any documentation of the following? Acute confusion Fluctuating confusion Fluctuation in severity throughout the day Altered mental status, mental status change	Yes, phrases similar to the ones listed are used in the notes	No	Don't know	
10.4	DSM criteria C: Is there any documentation of the following? Confused, confusion Muddled Hallucination, hallucinating Reorientation, reorientated Disorientation, disorientated, Encephalopathy, encephalopathic, Agitated, agitation Inappropriate behaviour Restless, unsettled Aggressive Wandering Refusing observations/ interventions Uncooperative, not cooperating, Pulling lines out Combative Speaking nonsense Paranoid MoCA < 24 AMTS < 7	Yes, phrases similar to the ones listed are used in the notes	No	Don't know	

10.5	DSM criteria D1: Is the participant functioning at their cognitive baseline?	Yes (they are at their neurocognitive baseline according to available sources of evidence)	No	Don't know	
10.6	DSM criteria D2: If delirium is likely, could this disturbance be better explained by a severely reduced level of arousal or coma? <i>If suffering from delirium, are the participant's symptoms better explained by being severely obtunded, sedated or unconscious with a Richmond Agitation Sedation Scale of 4 or less?</i>	Yes	No	Delirium not likely	
	Positive diagnosis of delirium from notes review either from:	Documented diagnosis of delirium in notes	DSM criteria responses: Yes to 10.2, 10.3, 10.4 No to 10.5, 10.6		
11.0	4 month follow up				
11.1	EQ-5D-5L				
11.2	EQ-VAS	0-100			
11.3	From when you had your operation, until 120 days after surgery, how many days have you spent in any hospital? Please include any hospital admissions (including your initial admission for surgery) and rehabilitation in hospitals. If you have				

	been out of hospital since the day of surgery and the surgery was day case then write '0'	
11.4	From when you had your operation, until 120 days after surgery, how many days have you spent from home due to convalescing with family/friends/in residential homes. Don't include days spent socialising away from home or hospital admissions here. If you have been at home since the day of surgery and the surgery was day case then write '0'	

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page/Line	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1/L4-6	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2/L10-18	Protocol paper so no results available
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4/L3- P5/L37	
Objectives	3	State specific objectives, including any prespecified hypotheses	P5/L39- P6/L24	
Methods				
Study design	4	Present key elements of study design early in the paper	P6/L26	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P6/L27- P7/L15- 37, P8/L39-47	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P8/L6- L37, P10/L2-22	
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P7/L17- P8/4, P9/L8- P10/L14, see also Appendix 2	Also see CRF appendix
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P9/L8- P10/L22	
Bias	9	Describe any efforts to address potential sources of bias	P3/L6, P3/L13- 16, P9/L34- 47, P10/L2-5	
Study size	10	Explain how the study size was arrived at	P13/L17- P14-L4	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P9/L15- 16, P9/L23-47	
Statistical methods	12	(a) Describe all statistical methods, including those used to	P10/L31-	

		control for confounding	P13/L15	
		(b) Describe any methods used to examine subgroups and interactions	P12/L38-46	
		(c) Explain how missing data were addressed	P10/L36-42	
		(d) If applicable, explain how loss to follow-up was addressed	Protocol paper so not possible	
		(e) Describe any sensitivity analyses	P11/L1-5	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Protocol paper so not possible.	
		(b) Give reasons for non-participation at each stage	Protocol paper so not possible.	
		(c) Consider use of a flow diagram	Protocol paper so not possible.	Protocol paper so not possible.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Protocol paper so not possible.	Protocol paper so not possible.
		(b) Indicate number of participants with missing data for each variable of interest	Protocol paper so not possible.	Protocol paper so not possible.
		(c) Summarise follow-up time (eg, average and total amount)	Protocol paper so not possible.	Protocol paper so not possible.
Outcome data	15*	Report numbers of outcome events or summary measures over time	Protocol paper so not possible.	Protocol paper so not possible.
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Protocol paper so not possible.	Protocol paper so not possible.
		(b) Report category boundaries when continuous variables were categorized	Protocol paper so not possible.	Protocol paper so not possible.
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Protocol paper so	Protocol paper so

			not possible.	not possible.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Protocol paper so not possible.	Protocol paper so not possible.
Discussion				
Key results	18	Summarise key results with reference to study objectives	Protocol paper so not possible.	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P3/L8-16	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Protocol paper so not possible.	Protocol paper so not possible.
Generalisability	21	Discuss the generalisability (external validity) of the study results	Protocol paper so not possible.	Protocol paper so not possible.
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P16/L40-44	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.